Switzerland, Francs
Switzerland
Document Type
Non-current assets
Total non-current assets
Current assets
Total current assets
Assets
Total assets
Treasury shares
Equity attributable to owners of parent
Equity attributable to Novartis AG shareholders
Equity
Total equity
Non-current provisions
Total non-current provisions
Total non-current liabilities
Non-current liabilities
Current liabilities
Total current liabilities
Liabilities
Total liabilities
Equity and liabilities
Total equity and liabilities
Property, plant and equipment
Goodwill
Intangible assets other than goodwill
Deferred tax assets
Other non-current non-financial assets
Current inventories
Other current financial assets
Cash and cash equivalents
Issued capital
Other reserves
Non-controlling interests
Trade and other non-current payables
Deferred tax liabilities
Other non-current financial liabilities
Other non-current non-financial liabilities
Other current financial liabilities
Current tax liabilities, current
Other current non-financial liabilities
Inventories
Share capital
Reserves
Other non-current assets
Provisions and other non-current liabilities
Financial debts
Financial debts and derivative financial instruments
Current income tax liabilities
Document and Entity Information
Investments accounted for using equity method
Investments in associated companies
Non-current assets [abstract]
Current assets [abstract]
Treasury shares
Equity and liabilities [abstract]
Equity [abstract]
Liabilities [abstract]
Non-current liabilities [abstract]
Current liabilities [abstract]
Disclosure of detailed information about property, plant and equipment [abstract]
Disclosure of detailed information about property, plant and equipment [table]
Classes of property, plant and equipment [axis]
Property, plant and equipment [member]
Land [member]
Land
Buildings [member]
Buildings
Construction in progress [member]
Construction in progress
Machinery [member]
Machinery and other equipment
Disclosure of detailed information about property, plant and equipment [line items]
Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]
Carrying amount [member]
Gross carrying amount [member]
Property, plant and equipment at beginning of period
Property, plant and equipment at end of period
Increase (decrease) through transfers from construction in progress, property, plant and equipment
Reclassifications
Additions other than through business combinations, property, plant and equipment
Additions
Disposals and retirements, property, plant and equipment
Disposals and derecognitions
Currency translation effects
Increase (decrease) through net exchange differences, property, plant and equipment
Depreciation, property, plant and equipment
Depreciation charge
Impairment charge
Impairment loss recognised in profit or loss, property, plant and equipment
Reversal of impairment loss recognised in profit or loss, property, plant and equipment
Property, plant and equipment impairment reversal
Net book value of Property, plant and equipment under finance lease contracts
Contractual commitments for acquisition of property, plant and equipment
Commitments for purchases of property, plant and equipment
Borrowing costs capitalised
Capitalisation rate of borrowing costs eligible for capitalisation
Borrowings, interest rate
Interest rate on borrowings for new additions
Capitalized borrowing costs
Capitalization rate used to determine the amount of borrowing costs eligible for capitalization
Statement [table]
Statement [line items]
Disclosure of property, plant and equipment [text block]
Property, plant and equipment
Property, plant and equipment [table text block]
Inventories Disclosure [abstract]
Disclosure of inventories [text block]
Inventories
Inventories by class
Inventory, Current [table]
Inventory [Axis]
Inventory [member]
Inventory, Raw Materials, Gross [member]
Raw material, consumables
Inventory, Work in progress, Gross [member]
Work in progress
Finished products
Inventory, Finished goods, Gross [member]
Inventory [line items]
Cost of inventories recognised as expense during period
Amount of inventory recognized as expense
Inventory write-down
Inventory provisions
Reversals of inventory provisions
Reversal of inventory write-down
Earnings per share [abstract]
Earnings per share [text block]
Earnings per share
Earnings per share
Earnings per share [table]
Earnings per share [line items]
Continuing and discontinued operations [axis]
Aggregate continuing and discontinued operations [member]
Continuing operations [member]
Discontinued operations [member]
Profit/loss attributable to shareholders of Novartis AG
Profit (loss), attributable to owners of parent
Weighted average number of ordinary shares outstanding
Weighted average number of shares outstanding used in the basic earnings per share
Dilutive effect of share options on number of ordinary shares
Adjustment for assumed exercise of equity-settled comepnsation plans
Adjusted weighted average number of ordinary shares outstanding
Weighted average number of shares in diluted earnings per share
Basic earnings (loss) per share from continuing operations
Basic earnings per share, Continuing operations
Basic earnings (loss) per share from discontinued operations
Basic earnings per share, Discontinued operations
Basic earnings (loss) per share
Total basic earnings per share
Diluted earnings (loss) per share from continuing operations
Diluted earnings (loss) per share from discontinued operations
Diluted earnings (loss) per share
Total diluted earnings per share
Diluted earnings per share, Continuing operations
Diluted earnings per share, Discontinued operations
Assets [abstract]
Statement of financial position [abstract]
Disclosure of detailed information about intangible assets [abstract]
Goodwill and intangible assets
Goodwill and intangible assets other than goodwill
Disclosure of intangible assets and goodwill [text block]
Disclosure of Movements of goodwill and intangible assets [text block]
Movements of goodwill and intangible assets
Allocation of net book values of goodwill and intangible assets by reporting segment
Assumptions used in the calculation of valuation [text block]
Assumptions used in the calculation of valuation
Allocation of net book values of goodwill and intangible assets by reporting segment [text block]
Disclosure of Income Tax [abstract]
Disclosure of income tax [text block]
Income taxes
Income Before Taxes [table text block]
Income before taxes
Current and deferred Income Tax Expense [table text block]
Current and deferred income tax expense
Analysis of Tax Rate [table text block]
Analysis of tax rate
Disclosure of Interest Expense and Other Financial Income and Expense [abstract]
Disclosure of interest expense [text block]
Interest expense and other financial income and expense
Interest Expense [table text block]
Interest expense
Other Financial Income and Expense [table text block]
Other financial income and expense
Disclosure of Deferred Tax Assets and Liabilities [abstract]
Disclosure of deferred taxes [text block]
Deferred tax assets and liablities
Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.
Temporary Differences On Which No Deferred Tax Assets Have Been Provided [table text block]
Temporary differences on which no deferred tax assets have been provided
Disclosure of temporary difference, unused tax losses and unused tax credits [text block]
Gross value of tax-loss carry-forwards
Significant Accounting Policies [abstract]
Respective Useful Lives of property, plant and equipment [table text block]
Respective Useful Lives of property, plant and equipment
Respective Useful Lives of Available-for-Use Intangible Assets [table text block]
Respective Useful Lives of Available-for-Use Intangible Assets
Description of accounting policy for subsidiaries [text block]
Scope of consolidation
Description of accounting policy for foreign currency translation [text block]
Foreign currencies
Description of accounting policy for business combinations [text block]
Acquisition of assets and businesses
Description of accounting policy for property, plant and equipment [text block]
Property plant and equipment
Description of accounting policy for goodwill [text block]
Goodwill
Description of accounting policy for Intangible assets available-for-use [text block]
Intangible assets available-for-use
Description of accounting policy for Intangible assets not yet available-for-use [text block]
Intangible assets not yet available-for-use
Goodwill and intangible assets other than goodwill
Description of accounting policy for Impairment of associated companies accounted for at equity [text block]
Impairment of associated companies accounted for at equity
Description of accounting policy for financial assets [text block]
Description of accounting policy for measuring inventories [text block]
Inventories
Description of accounting policy for trade and other receivables [text block]
Trade receivables
Description of accounting policy for provisions [text block]
Legal and environmental liabilities
Description of accounting policy for contingent liabilities and contingent assets [text block]
Contingent consideration
Description of accounting policy for employee benefits [text block]
Defined benefit pension plans and other post retirement benefits
Description of accounting policy for treasury shares [text block]
Treasury Shares
Description of accounting policy for recognition of revenue [text block]
Revenue recognition
Description of accounting policy for research and development expense [text block]
Research and development
Description of accounting policy for share-based payment transactions [text block]
Share based compensation
Description of accounting policy for government grants [text block]
Government grants
Description of accounting policy for decommissioning, restoration and rehabilitation provisions [text block]
Restructuring charges
Description of accounting policy for income tax [text block]
Income taxes
Description of accounting policy for non-current assets or disposal groups classified as held for sale [text block]
Non-current assets held for sale or held for distribution to owners
Disclosure of expected impact of initial application of new standards or interpretations [text block]
Impact of adopting significant new IFRS standards
Property, plant and equipment [abstract]
Range [axis]
Range [domain]
Bottom of range [member]
Top of range [member]
Computer equipment [member]
Furniture and vehicles [member]
Furniture and vehicles
Classes of intangible assets other than goodwill [axis]
Intangible assets other than goodwill [member]
Brand names [member]
Other intangible assets [member]
Technology-based intangible assets [member]
Currently marketed products [member]
Income statement location [axis]
Income statement location [member]
Cost of sales or Research and Development [member]
Interest expense [abstract]
Expense due to unwinding of discount on provisions
Interest expense
Expense arising from discounting long-term liabilities
Interest expense
Total Interest Expense
Other financial income and expense [abstract]
Income on forward contracts and options
Gains (losses) on net monetary position
Monetary loss from hyperinflation accounting
Foreign exchange gain (loss)
Currency result, net
Major components of tax expense (income) [abstract]
Geographical areas [axis]
Geographical areas [domain]
Country of domicile [member]
Foreign countries [member]
Switzerland
Foreign
Profit (loss) before tax
Accounting profit
Income before taxes
Total Income before taxes
Tax expense (income), continuing operations
Income tax expense
Income tax expense
Total Income Tax Expense
Reconciliation of average effective tax rate and applicable tax rate [abstract]
Applicable tax rate from discontinued operations
Applicable tax rate
Tax rate, effect of credits and allowances
Effect of tax credits and allowances
Tax rate, effect of write off of deferred tax assets
Effect of write off of deferred tax assets
Tax rate, effect from write down and reversal of write down of invest subsidiaries
Effect of write down and reversal of write down of investments in subsidiaries
Effect of tax benefits expiring in 2017
Tax rate, effect from benefits expiring
Effect of non-deductible losses in Venezuela
Tax rate effect of adjustments for current tax of prior periods
Effect of prior year items
Effect of other items
Other tax rate effects for reconciliation between accounting profit and tax expense (income)
Average effective tax rate continuing operations
Effective tax rate for continuing operations
Effective tax rate for discontinued operations
Average effective tax rate discontinued operations
Effective tax rate from continuing operations
Average effective tax rate
Deferred tax assets and liabilities [abstract]
Assets and liabilities [axis]
Assets and liabilities [domain]
Pensions and other benefit obligations of associates [member]
Tax loss carryforwards [member]
Other assets, provisions and accruals [member]
Deferred tax assets
Deferred tax liabilities
Deferred tax liability (asset)
Net deferred tax balance
Credited/(charged) to income
Deferred tax expense (income) recognised in profit or loss
Deferred tax relating to items credited (charged) directly to equity
Charged to equity
Income tax relating to components of other comprehensive income
Credited/(charged) to other comprehensive income
Increase (decrease) through business combinations, deferred tax liability (asset)
Impact of business combinations
Increase (decrease) through other movements deferred tax liability (asset)
Other movements
Offsetting of deferred tax assets and liabilities within the same tax jurisdiction
Temporary differences on which no deferred tax assets have been provided [abstract]
Investments in subsidiaries [member]
Goodwill from acquisitions [member]
Deductible temporary differences for which no deferred tax asset is recognised
Temporary differences on which no deferred tax has been provided as they are permanent in nature
Disclosure of temporary difference, unused tax losses and unused tax credits [abstract]
Disclosure of temporary difference, unused tax losses and unused tax credits [table]
Balance sheet treatment [axis]
Balance sheet treatment [member]
Capitalized [member]
Not capitalized [member]
Year of expiry [axis]
Year of expiry [member]
One year [member]
Two years [member]
Three years [member]
Four years [member]
Five years [member]
More than five years [member]
Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets
Value of tax loss carryforwards expired
Tax loss carryforwards expired
Deferred tax asset expected to have an impact on current taxes payable after more than 12 months
Deferred tax liabilities expected to have an impact on current taxes payable after more than 12 months
Unremitted earnings retained by consolidated entities for reinvestment
Provision for income taxes on unremitted earnings
Net capital losses on available-for-sale securities
Gains (losses) on available-for-sale financial assets
Disclosure of financial and other non-current assets [abstract]
Disclosure of financial and other non-current assets [text block]
Financial and other non-current assets
Disclosure of financial assets [table text block]
Financial assets
Disclosure of other non-current assets [table text block]
Other non-current assets
Disclosure of minimum finance lease payments [table text block]
Minimum finance lease payments
Other current assets [abstract]
Disclosure of other current assets [text block]
Other current assets
Other current assets [table text block]
Other current assets
Current value added tax receivables
VAT Receivable
Withholding tax recoverable
Current prepaid expenses associated companies
Prepaid expenses - associated companies
Receivables associated companies
Total other current assets
Other current non-financial assets
Disclosure of marketable securities deposits derivative instruments and cash equivalents [abstract]
Disclosure of marketable securities deposits derivative instruments and cash and cash equivalents
Marketable securities, time deposits, and derivative financial instruments
Cash and cash equivalents [table text block]
Cash and cash equivalents
Debt instruments held
Debt securities
Equity instruments held
Equity securities
Fund instruments held
Fund investments
Commodities
Short-term deposits, not classified as cash equivalents
Time deposits and short-term investments with original maturity more than 90 days
Derivative financial instruments
Derivative financial assets
Interest receivable
Accrued interest on debt securities and time deposits
Current accounts
Cash
Cash and cash equivalents [abstract]
Total cash and cash equivalents
Time deposits and short term investments with original maturity less than 90 days
Cash equivalents
Debt securities denominations [abstract]
Debt securities held
Computer hardware
Movement in deferred tax balance [roll forward]
Net deferred tax balance at beginning of period
Net deferred tax balance at end of period
Disclosure of financial assets [abstract]
Contingent Consideration Receivable
Contingent consideration receivables
Financial assets
Non-current financial assets
Total financial assets
Non-current loans and receivables
Non-current trade receivables
Non-current financial assets available-for-sale
Available-for-sale long-term financial investments
Long-term receivables from customers
Long-term loans, advances and security deposits
Disclosure of other non-current assets [abstract]
Other non-current assets
Total other non-current assets
Deferred compensation plans assets
Prepaid post-employment benefit plans assets
Maturity [axis]
Maturity [domain]
Not later than one year [member]
Later than one year and not later than five years [member]
Later than five years [member]
Not later than one year
Between one and five years
Later than five years
Finance lease provision
Provision
Non-current finance lease receivables
Profit or loss [abstract]
Consolidated income statements [abstract]
Revenue from sale of goods
Net sales
Other revenue
Other revenues
Cost of sales
Cost of goods sold
Gross profit
Gross profit
Sales and marketing expense
Marketing and Sales
Research and development expense
Research and development
Other income
Profit (loss) from operating activities
Operating income
Share of profit (loss) of associates and joint ventures accounted for using equity method
Loss from associated companies
Profit (loss) from continuing operations
Net income
Income taxes
Profit (loss) from discontinued operations
Net income from discontinued operations
Profit (loss)
Net income
Profit (loss), attributable to [abstract]
Profit (loss), attributable to non-controlling interests
Non-controlling interests
Basic earnings per share [abstract]
Continuing operations
Discontinued operations
Diluted earnings per share [abstract]
Continuing operations
Discontinued operations
Income before taxes
Disclosure of classes of share capital [abstract]
Movement in the share capital [table text block]
Schedule disclosing information related to movement in the share capital
Movement in the shares [table text block]
Schedule disclosing information related to movement in the shares
Disclosure of classes of share capital [table]
Disclosure of classes of share capital [line items]
Classes of share capital [axis]
Classes of share capital [domain]
Increase (decrease) in equity
Movement in the year
Treasury shares [member]
Ordinary shares [member]
Number of shares issued and fully paid
Number of shares outstanding
Increase (decrease) in number of shares outstanding
Number of shares outstanding at beginning of period
Number of shares outstanding at end of period
Number of shares issued and fully paid at beginning of period
Number of shares issued and fully paid at end of period
Share capital at beginning of period
Share capital at end of period
Treasury shares at end of period
Treasury shares at beginning of period
Equity at end of period
Equity at beginning of period
Purchase of treasury shares
Sale or issue of treasury shares
Disclosure of non-adjusting events after reporting period [abstract]
Disclosure of events after reporting period [text block]
Events subsequent to the December 31 consolidated balance sheet date
Subsequent Event Typ [axis]
Subsequent Event Type [member]
Subsequent Event [member]
Dividends proposed or declared before financial statements authorised for issue but not recognised as distribution to owners
Commitments and contingencies [abstract]
Disclosure of commitments and contingencies [text block]
Commitments and contingent liabilities
Disclosure of significant transactions [abstract]
Disclosure of Significant transactions [text block]
Significant acquisitions of businesses
Disclosure of financial liabilities [abstract]
Disclosure of financial liabilities [text block]
Non-current financial debt
Disclosure of current financial debt and derivative instruments [abstract]
Disclosure of current financial debts and derivative instruments [text block]
Current financial debts and derivative financial instruments
Disclosure of non-current portion of non-current borrowings by type [table text block]
Disclosure of non-current portion of non-current borrowings by type
Disclosure of detailed information about borrowings
Disclosure of detailed information about borrowings [table text block]
Disclosure of non-current financial debts including current portion by maturity [table text block]
Non-current financial debts including current portion by maturity
Disclosure of non-current financial debts including current portion by currency [table text block]
Non-current financial debts including current portion by currency
Disclosure of comparison of balance sheet and fair value of total non-current financial debts including current portion [table text block]
Comparison of balance sheet and fair value of total non-current financial debts including current portion
Disclosure of collaerallized non-current financial debts and pledged assets [table text block]
Collaerallized non-current financial debts and pledged assets
Current financial debts and derivative financial instruments
Disclosure of Leasing commitments [table text block]
Research and development commitments
Disclosure of research and development commitments [table text block]
Research and Development and other intangible purchase commitments
Leasing commitments [abstract]
Schedule for commitments under fixed term operating leases [table]
Schedule for commitments under fixed term operating leases [line items]
Later than one year and not later than two years [member]
Later than two years and not later than three years [member]
Later than three years and not later than four years [member]
Later than four years and not later than five years [member]
Research and development and other intangible asset purchase commitments [abstract]
Schedule for commitments under research and development and other intangible asset purchase [table]
Schedule for commitments under research and development and other intangible asset purchase [line items]
Current financial debt and derivative financial instruments [table]
Current financial debt and derivative financial instruments [line items]
Interest bearning accounts of associates payable on demand
Current borrowings
Bank and other financial debt
Commercial papers issued
Commercial paper
Current portion of non-current borrowings
Current portion of non-current financial debt
Credit derivative, fair value
Derivative financial liabilities
Derivative financial instruments
Weighted average interest rate, associates
Total current financial debt and derivative financial instruments
Interest expense
Disclosure of components of non-current financial debts [abstract]
Disclosure of components of non-current financial debts [table]
Straight bonds
Bonds issued
Total including current portion of non-current financial debt
Borrowings
Less current portion of non-current financial debt
Total non-current financial debts
The amount of outstanding funds that the entity is obligated to repay
Later than five years and not later than six years [member]
Later than six years [member]
Later than six years
Others
Disclosure of the collateralized non-current financial debt and pledged assets [abstract]
Disclosure of the collateralized non-current financial debt and pledged assets [table]
Disclosure of the collateralized non-current financial debt and pledged assets [line items]
Property, plant and equipment, pledged as security
Non-current financial debts covered by collateral
Total amount of collateralized non-current financial debts
Total net book value of property, plant and equipment pledged as collateral for non-current financial debts
Disclosure of detailed information about borrowings [abstract]
Disclosure of detailed information about borrowings [table]
Disclosure of detailed information about borrowings [line items]
Borrowings by name [axis]
Borrowings by name [domain]
4.25% EUR 1 500 million bond 2009/2016 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 99.757% [member]
4.4% USD 1 000 million bond 2010/2020 of Novartis Capital Corporation, New York United States, issued at 99.237% [member]
2.4% USD 1 500 million bond 2012/2022 of Novartis Capital Corporation, New York United States, issued at 99.225% [member]
3.7% USD 500 million bond 2012/2042 of Novartis Capital Corporation, New York United States, issued at 98.325% [member]
3.4% USD 2 150 million bond 2014/2025 of Novartis Capital Corporation, New York United States, issued at 99.287% [member]
4.4% USD 1 850 million bond 2014/2044 of Novartis Capital Corporation, New York United States, issued at 99.196% [member]
0.75% EUR 600 million bond 2014/2021 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 99.134% [member]
1.625% EUR 600 million bond 2014/2026 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 99.697% [member]
0.25% CHF 500 million bond 2015/2025 of Novartis AG Basel Switzerland, issued at 100.64% [member]
0.625% CHF 550 million bond 2015/2029 of Novartis AG Basel Switzerland, issued at 100.502% [member]
1.050% CHF 325 million bond 2015/2035 of Novartis AG Basel Switzerland, issued at 100.479% [member]
3.0% USD 1 750 million bond 2015/2025 of Novartis Capital Corporation, New York United States, issued at 99.010% [member]
4.0% USD 1 250 million bond 2015/2045 of Novartis Capital Corporation, New York United States, issued at 98.029% [member]
0.125% EUR 1 250 million bond 2016/2023 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 99.127% [member]
0.625% EUR 500 million bond 2016/2028 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 98.48% [member]
Notional amount
Borrowings, original currency
Borrowings, maturity
Borrowings, lender
Borrowings, premium discount
Disclosure of fair value measurement of liabilities [abstract]
Disclosure of fair value measurement of liabilities [table]
Disclosure of fair value measurement of liabilities [line items]
Levels of fair value hierarchy [axis]
Levels of fair value hierarchy [domain]
Level 1 of fair value hierarchy [member]
Level 2 of fair value hierarchy [member]
Level 3 of fair value hierarchy [member]
Other non-current financial debt
Others
Total
Fair value by measurement basis [axis]
Fair value by measurement basis [member]
Fair value disclosure item amounts [member]
Fair values
Balance sheet
Statement of comprehensive income [abstract]
Net income
Components of other comprehensive income that will not be reclassified to profit or loss, net of tax [abstract]
Items that will never be recycled into the consolidated income statement
Other comprehensive income, net of tax, available-for-sale financial assets
Fair value adjustments on marketable securities, net of taxes
Fair value adjustments on deferred cash flow hedges, net of taxes
Other comprehensive income, net of tax, financial instruments
Total fair value adjustments on financial instruments, net of taxes
Other comprehensive income, net of tax, exchange differences on translation
Currency translation effects, net of taxes
Other comprehensive income that will be reclassified to profit or loss, net of tax
Total of items that are or may be recycled
Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]
Other comprehensive income - Items that are or may be recycled into the consolidated income statement
Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans
Actuarial gains/losses from defined benefit plans, net of taxes
Comprehensive income
Total comprehensive income
Comprehensive income attributable to [abstract]
Total comprehensive income for the period attributable to:
Comprehensive income, attributable to owners of parent
Shareholders of Novartis AG
Comprehensive income, attributable to non-controlling interests
Non-controlling interests
Continuing operations
Discontinued operations
Other financial income and expense
Total other financial income and expense
Other financial income and expense
Other financial income and expense
Attributable to
Statement of cash flows [abstract]
Statement of changes in equity [abstract]
Statement of changes in equity [table]
Components of equity [axis]
Components of equity [domain]
Equity attributable to owners of parent [member]
Non-controlling interests [member]
Issued capital [member]
Retained earnings [member]
Statement of changes in equity [line items]
Other comprehensive income
Dividends recognised as distributions to owners
Dividends
Increase/decrease of treasury share repurchase obligation under a share buyback trading plan
Increase (decrease) through changes in ownership interests in subsidiaries that do not result in loss of control, equity
Impact of change in ownership of consolidated entities
Total of other equity movements
Fair value adjustments related to divestments
Share capital
Treasury shares
Retained earnings
Other comprehensive income, net of tax, fair value adjustments on deferred cash flow hedges
Interest received, classified as operating activities
Interest received
Interest paid, classified as operating activities
Interest paid
Income taxes paid (refund), classified as operating activities
Taxes paid
Net cash flows from operating activities before working capital and provision changes
Payments out of provisions and other net cash movements in non-current liabilities
Changes in working capital and other operating cash flow items
Cash flows from (used in) operating activities, continuing operations
Net cash flows from operating activities from continuing operations
Cash flows from (used in) operating activities, discontinued operations
Net cash flows from operating activities from discontinued operations
Cash flows from (used in) operating activities
Net cash flows from operating activities
Purchase of property, plant and equipment, classified as investing activities
Purchases of property, plant and equipment
Proceeds from sales of property, plant and equipment
Purchase of intangible assets, classified as investing activities
Purchases of intangible assets
Proceeds from sales of intangible assets, classified as investing activities
Proceeds from sale of intangible assets
Purchase of other long-term assets, classified as investing activities
Purchases of other non-current assets
Proceeds from sales of other long-term assets, classified as investing activities
Proceeds from sale of other non-current assets
Cash flows from (used in) investing activities, continuing operations
Cash flows used in investing activities from continuing operations
Cash flows from (used in) investing activities, discontinued operations
Cash flows used in/from investing activities from discontinued operations
Cash flows from (used in) investing activities
Net cash flows (used in)/from investing activities
Payments to acquire or redeem entity's shares
Purchases of treasury shares
Proceeds from exercise of options and other treasury share transactions
Cash flows from (used in) financing activities
Net cash flows from/(used in) financing activities
Effect of exchange rate changes on cash and cash equivalents
Increase (decrease) in cash and cash equivalents
Net change in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Cash flows before working capital and provision changes
5.125% USD 3 000 million bond 2009/2019 of Novaritis Securities Investment Ltd., Hamilton, Bermuda issued at 99.822% [member]
Borrowings, issuance date
Currency, others [member]
Less current portion of non-current financial debt
Disclosure of detailed information about business combination [abstract]
Disclosure of detailed information about business combination [table]
Disclosure of detailed information about business combination [line items]
Subsidiaries [axis]
Subsidiaries [domain]
Subsidiaries [member]
Operating income [member]
Transcend Medical Inc [member]
Transcend Medical Inc.
Selexys Pharmaceuticals Corporation [member]
Selexys Pharmaceuticals Corporation
Ziarco Group Limited [member]
Ziarco Group Limited
Encore Vision, Inc [member]
Encore Vision, Inc.
Eli Lilly and Company [member]
Eli Lilly and Company
GSK Oncology Products [member]
GSK Oncology Products
GSK Vaccines [member]
GSK Vaccines
GSK Consumer Healthcare [member]
GSK Consumer Healthcare
GSK Total Transaction [member]
GSK Total Transaction
CSL [member]
CSL
Spinifex [member]
Spinifex
Admune Theraputics [member]
Admune Theraputics
Consideration transferred, acquisition-date fair value
Portion of consideration paid (received) consisting of cash and cash equivalents
Contingent liabilities recognised as of acquisition date
Identifiable assets acquired (liabilities assumed)
Additional recognition, goodwill
Acquisition-date fair value of equity interest in acquiree held by acquirer immediately before acquisition date
Gain (loss) recognised as result of remeasuring to fair value equity interest in acquiree held by acquirer before business combination
Percentage of voting equity interests acquired
Proceeds from disposal of non-current assets or disposal groups classified as held for sale and discontinued operations
Description of arrangement for contingent consideration arrangements and indemnification assets
Disclosure of provisions and other current liabilities [abstract]
Disclosure of provisions and other current liabilities explanatory [text block]
Provisions and other current liabilities
Disclosure of acquisition of businesses [abstract]
Disclosure of business combinations [text block]
Acquisition of businesses
Disclosure of defined benefit plans [abstract]
Disclosure of employee benefits [text block]
Schedule of provisions and other current liabilities [table text block]
Provisions and other current liabilities
Provisions for reduction of revenue [table text block]
Provisions for reduction of revenue
Restructuring provisions movements [table text block]
Restructuring provisions movements
Fair value of assets and liabilities arising from acquisitions [table text block]
Fair value of assets and liabilities acquired through business combinations
Disclosure of defined benefit plans [table text block]
Summary of the funded and unfunded defined benefit obligation for pension and other post retirement benefit plans table
Disclosure of net defined benefit liability (asset) [table text block]
Reconciliation of the asset/net liability table
Breakdown of defined benefit obligation for pension plans and other post-employment benefit [table text block]
Breakdown of defined benefit obligation for pension plans and other post-employment benefit
Principal weighted average actuarial assumptions
Schedule of sensitivity analysis for actuarial assumptions [table text block]
The sensitivity of the defined benefit pension obligation to the principal actuarial assumptions
The healthcare cost trend rate assumptions used for other post-employment benefits
The fair value of plan asset allocation of funded defined benefit pension plans
The expected future cash flows in respect of pension and other post- employment benefit plans
Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [abstract]
Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [table]
Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [line items]
Currently marketed products intangible assets recognised as of acquisition date
Currently marketed products
Acquired research and development intangible assets recognised as of acquisition date
In-procees research and development
Other intangible assets recognised as of acquisition date
Other intangible assets
Deferred tax assets recognised as of acquisition date
Deferred tax assets
Inventory recognised as of acquisition date
Inventories
Trade receivables and other current assets recognised as of acquisition date
Financial and other current assets recognised as of acquisition date
Cash and cash equivalents recognised as of acquisition date
Cash and cash equivalents
Net identifiable assets acquired
Goodwill expected to be deductible for tax purposes
Provisions and other current liabilities [table]
Potentially refundable consideration from acquisition
Fair value of potentially refundable contingent consideration
Contract right of first negotiation term
Revenue of acquiree since acquisition date
Revenue of acquiree full year
Sale of business assets arising from contingencies amount recognized
Sale of business assets arising from contingencies amount recognized other than at fair value
Sale of business, contingent consideration arrangements, range of outcomes, value, high
Sale of business, contingent option arrangements, range of outcomes, value, high
Sale of business, contingent option arrangements, fee paid
Investments in subsidiaries, joint ventures and associates
Percentage of voting equity interests contributed
Transaction related costs
Transaction related costs paid
Impairment loss
Reversal of impairment loss
Provisions and other current liabilities [line items]
Current restructuring provision
Restructuring provisions
Accrued royalties payable classified as current
Accruals for royalties
Accrual for taxes other than income taxes
Short-term employee benefits accruals
Accruals for compensation and benefits including social security
Current legal proceedings provision
Provisions for product liabilities, governmental investigations and other legal matters
Other current payables
Other provisions and other current liabilities
Provisions for deductions from revenue [roll forward]
Classes of other provisions [axis]
Classes of other provisions [domain]
Refunds provision [member]
Deductions from revenue
Other provisions
Provision at end of period
Provision at beginning of period
Decrease through loss of control of subsidiary, other provisions
Provisions related to discontinued operations
Acquisitions through business combinations, other provisions
Impact of business combinations
Additional provisions, other provisions
Additions to provisions
Provision used, other provisions
Payments/utilizations
Changes in offset against gross trade receivables
Increase (decrease) through net exchange differences, other provisions
Currency translation effects
Unused provision reversed, other provisions
Cash payments
Releases of provisions
Restructuring provision [member]
Restructuring provision
Restructuring provisions movements [roll forward]
Disclosure of trade receivables [abstract]
Disclosure of trade receivables explanatory [text block]
Trade receivables
Provisions for trade receivables [table text block]
Provisions for trade receivables
Trade receivables provision movements [table text block]
Trade receivables provision movements
Overdue amounts and related provisions [table text block]
Overdue amounts and related provision
Trade receivables denominated in other currencies [table text block]
Trade receivables denominated in other currencies
Disclosure of provision matrix [abstract]
Disclosure of provision matrix [table]
Disclosure of provision matrix [line items]
Classes of financial instruments [axis]
Classes of financial instruments [domain]
Trade receivables [member]
Trade receivables
Total trade receivables, net
Provisions for doubtful trade receivables related to discontinued operations
Provisions for doubtful trade receivables charged to the consolidated income statement
Utilization of provisions for doubtful trade receivables
Analysis of overdue amounts [table]
Past due status [axis]
Past due status [member]
Current [member]
Analysis of overdue amounts [line items]
Disclosure of receivables denominated in various currencies [table]
Current trade receivables from closely monitored countries
Current trade receivables from closely monitored countries past due more than one year
Current trade receivables from closely monitored countries past due more than one year, provisions recorded
Disclosure of subsidiaries [abstract]
Disclosure of subsidiaries [text block]
Principal subsidiaries and associated companies
Principal Group subsidiaries and associated companies [table text block]
Principal Group subsidiaries and associated companies
Disclosure of subsidiaries [table]
Disclosure of subsidiaries [line items]
Name of subsidiary
Principal place of business of subsidiary
Country of incorporation of subsidiary
Proportion of ownership interest in subsidiary
Proportion of voting rights held in subsidiary
Share/paid-in capital
Societe par actions SANDOZ, Algiers [member]
Novartis Argentina S.A., Ciudad de Buenos Aires [member]
Alcon Laboratorios S.A., Buenos Aires [member]
Roche Holding AG, Basel [member]
Disclosure of defined benefit plans [table]
Disclosure of defined benefit plans [line items]
Disclosure of net defined benefit liability (asset) [line items]
Rest of the world
Defined benefit plans [domain]
Domestic defined benefit plans [member]
Foreign defined benefit plans [member]
Concentration of major plans, geographic
Description of the major plans and the concentration of the Group's DBO by geography.
Description of plan amendments, curtailments and settlements
Net Pre-tax curtailment gain (loss)
Defined benefit plans [axis]
Retirement plan type [axis]
Retirement plan type [member]
Pension plan [member]
Other post-employment benefit plans [member]
Pension plans
Other post-employment benefit plans
Defined benefit obligation, at present value
Benefit obligation at beginning of period
Benefit obligation at end of period
Current service cost, net defined benefit liability (asset)
Current service cost
Administrative expenses
Actuarial gains (losses) arising from changes in financial assumptions, net defined benefit liability (asset)
Remeasurement losses/(gains) arising from changes in financial assumptions
Actuarial gains (losses) arising from changes in demographic assumptions, net defined benefit liability (asset)
Remeasurement losses/(gains) arising from changes in demographic assumptions
Currency translation effects
Payments from plan, net defined benefit liability (asset)
Benefit payments
Contributions to plan by plan participants, net defined benefit liability (asset)
Contributions of employees
Increase (decrease) through acquisitions, divestments or transfers, benefit obligation
Effect of acquisitions, divestments or transfers
Plan assets, at fair value
Fair value of plan assets at beginning of period
Fair value of plan assets at end of period
Currency translation effects
Contributions to plan by employer, net defined benefit liability (asset)
Novartis contributions
Increase (decrease) through acquisitions, divestments or transfers, defined benefit liability (asset)
Effect of acquisitions, divestments or transfers
Defined benefit plan, change in benefit obligation [roll forward]
Defined benefit plan, change in fair value of plan assets [roll forward]
Surplus (deficit) in plan
Funded status
Defined benefit plan, change in limitation on recognition of fund surplus [roll forward]
Net defined benefit liability (asset)
Net asset/(liability) in the balance sheet at end of period
Limitation on recognition of fund surplus
Limitation on recognition of fund surplus at beginning of period
Limitation on recognition of fund surplus at end of period
Disclosure of net defined benefit liability (asset) [table]
Defined benefit plan, change in net liability [roll forward]
Net asset/(liability) at end of period
Net asset/(liability) at beginning of period
Interest expense (income), net defined benefit liability (asset)
Net interest expense
Gain (loss) on remeasurement, net defined benefit liability (asset)
Remeasurements
Increase (decrease) through changes in foreign exchange rates, net defined benefit liability (asset)
Currency translation effects
Increase (decrease) through acquisitions, divestments or transfers, net defined benefit liability (asset)
Effect of acquisitions, divestments or transfers
Amounts recognized in the consolidated balance sheet [abstract]
Accrued liability for defined benefit pension plans
Defined benefit pension plan, accrued benefit liability
Breakdown of defined benefit obligation for pension plans [table]
Obligation by type [axis]
Obligation by type [member]
Unfunded [member]
Obligation by type
Unfunded
Active [member]
Active
Deferred pensioners [member]
Deferred pensioners
Pensioners [member]
Pensioners
Schedule of defined benefit plans disclosures [table]
Actuarial assumption of discount rates
Discount rate
Actuarial assumption of expected rates of pension increases
Expected rate of pension increase
Actuarial assumption of expected rates of salary increases
Expected rate of salary increase
Actuarial assumption of expected rates of interest on savings account
Interest on savings account
Defined benefit assumption life expectancy, male
Current average life expectancy for a 65-year-old male in years
Defined benefit assumption life expectancy, female
Current average life expectancy for a 65-year-old female in years
Disclosure of sensitivity analysis for actuarial assumptions [table]
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Actuarial assumptions [axis]
Actuarial assumptions [domain]
Actuarial assumption of discount rates [member]
Discount rate
Life expectancy [member]
Life expectancy
Actuarial assumption of expected rates of pension increases [member]
Rate of pension increase
Actuarial assumption of expected rates of interest on savings account [member]
Interest on savings account
Actuarial assumption of expected rates of salary increases [member]
Salary increase
Change in actuarial assumption [axis]
Change in actuarial assumption [member]
Decrease, 25 basis point [member]
25 basis point decrease
Increase, 25 basis point [member]
25 basis point increase
Increase, 1 year [member]
1 year increase
Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption
Increase (decrease) in defined benefit obligation due to reasonably possible decrease in actuarial assumption
Schedule of health care cost trend rates [table]
Healthcare cost trend rate assumed for next year
Year that the rate reaches the ultimate trend rate
Schedule of allocation of plan assets [table]
Classes of assets [axis]
Classes of assets [domain]
Equity investments [member]
Equity securities
Debt securities [member]
Debt securities
Real estate
Alternative investments [member]
Alternative investments
Cash and other investments [member]
Cash and other investments
Defined benefit plan, target plan asset allocations range minimum
Defined benefit plan, target plan asset allocations range maximum
Shares held by defined benefit plan
Value of shares held by defined benefit plan
Defined contribution pension and other post-retirement plans disclosure [abstract]
Defined contribution pension and other post-retirement plans disclosure [table]
Defined contribution pension and other post-retirement plans disclosure [line items]
Post-employment benefit expense, defined contribution plans
Schedule of expected benefit payments [table]
Defined benefit plan, expected future benefit payment [abstract]
Defined benefit plan, expected future employer contributions [abstract]
Novartis Group contributions
Expected future benefit payments
Contributions, next fiscal year (estimated)
Past service costs and settlements
Past service costs and gains losses arising from settlements, defined benefit liability (asset)
Defined benefit plan, expected future employer contributions, next fiscal year
Analysis of income and expense [abstract]
Disclosure of discontinued operations [text block]
Discontinued operations
Disclosure of details to the consolidated statements of cash flows [abstract]
Details to the consolidated statements of cash flows
Disclosure of cash flow statement [text block]
Adjustments for non-cash items from continuing operations [table text block]
Adjustments for non-cash items from continuing operations
Cash flows from changes in working capital and other operating cash flow items included in operating cash flow from continuing operations
Cash flows arising from acquisitions and divestments of businesses [table text block]
Cash flows related to acquisitions of businesses
Cash flows from discontinued operations [table text block]
Cash flows from discontinued operations
Consolidated income statement segmentation [table text block]
Consolidated income statement segmentation
Expenses included in net income [table text block]
Expenses included in net income
Revenue from sale of goods, sales to continuing segments
Sales to continuing segments
Segments [axis]
Segments [domain]
Vaccines [member]
Consumer Health [member]
Vaccines
Consumer Health
Corporate
Operating income/loss of discontinued operations
Operating income/loss of discontinued operations
Income tax expense of discontinued operations
Income tax expense of discontinued operations
Net income from discontinued operations
Depreciation expense
Amortisation expense
Impairment loss (reversal of impairment loss) recognised in profit or loss
Expense from share-based payment transactions with employees
Equity-based compensation of Novartis equity plans
Classes of intangible assets and goodwill [domain]
Property, plant and equipment
Financial assets impaired [member]
Financial assets
Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract]
Depreciation, amortization and impairments on:
Adjustments for losses (gains) on disposal of non-current assets
(Gains)/losses on disposal on property, plant and equipment; intangible assets; and other adjustments on financial assets; and other non-current assets, net
Adjustment for share based payments
Equity-settled compensation plans
Adjustment for change in provisions and other non-current liabilities
Change in provisions and other non-current liabilities
Adjustments for finance income (cost)
Net financial expense
Adjustments for decrease (increase) in inventories
(Increase)/decrease in inventories
Adjustments for decrease (increase) in trade accounts receivable
Increase/(decrease) in trade receivables
Adjustments for decrease (increase) in trade accounts payable
(Decrease)/increase in trade payables
Other inflows (outflows) of cash
Change in other net current assets and other operating cash flow items
Total
Increase (decrease) in cash and cash equivalents, discontinued operations
Acquisitions and divestments [axis]
Acquisitions and divestments [member]
Acquisitions [member]
Acquisitions
Divestments [member]
Divestments
Financial and other assets including deferred tax assets
Other assets [member]
Other intangible assets
Technologies
Brand names
Inventories
Cash inflow (outflow), currency translation effects
Currency translation effects
Currency translation effects
Cash inflow (outflow), acquired/(divested) liquity
Acquired/(divested) liquity
Subtotal
Cash inflow (outflow) from Net identifiable assets (acquired) or divested, currency translation effects, Acquired/(divested) liquidity and fair value of previously held equity interests.
Cash provided by refinancing of intercompany financial debt, net
Refinancing of intercompany financial debt, net
Cash provided by refinancing of intercompany financial debt, net.
Cash inflow (outflow), Goodwill
Goodwill
Divestment gain
Cash inflow (outflow), Divestment gain (loss)
Taxes paid and other portfolio transformation related cash flows
Receivables and payables contingent consideration, net
Other payments and deferred consideration, net
(Deferred)/prepaid portion of sales price
(Deferred)/prepaid portion of sales price to cash flows (used in) provided by acquisitions/divestments of businesses.
Contingent consideration paid
Business combinations [axis]
Business combinations [domain]
Change, 25 basis point [member]
25 basis point change
Dividends payable, amount per share
Treasury shares acquired to be held
Treasury shares acquired to be cancelled
Other share purchases
Share-purchase of treasury shares
Treasury shares acquired to be held, equity impact
Treasury shares acquired for cancellation, equity impact
Other share purchases, equity impact
Comprehensive income [abstract]
Changes in consolidated statements of comprehensive income [text block]
Changes in consolidated statements of comprehensive income
Schedule of comprehensive income [table text block]
Comprehensive income
Fair value adjustments financial instruments reconciliation [table text block]
Fair value adjustments financial instruments reconciliation
Schedule of defined benefit plan amounts recognized in other comprehensive income [table text block]
Schedule of defined benefit plan amounts recognized in other comprehensive income
Disclosure of terms and conditions of share-based payment arrangement [abstract]
Disclosure of share-based payment arrangements [text block]
Equity-based participation plans for employees
Disclosure of transactions between related parties [abstract]
Disclosure of related party [text block]
Transactions with related parties
Post-employment benefits for employees
Officer and director compensation [table text block]
Executive Officers and Non-Executive Directors Compensation
Disclosure of number and weighted average remaining contractual life of outstanding share options [text block]
Disclosure of range of exercise prices of outstanding share options [text block]
Schedule of share-based compensation, activity [table text block]
Schedule of share-based compensation, activity
Schedule of unvested restricted stock units roll forward
Disclosure of range of exercise prices of outstanding share options
Disclosure of number and weighted average remaining contractual life of outstanding share options
Disclosure of transactions between related parties [table]
Disclosure of transactions between related parties [line items]
Categories of related parties [axis]
Categories of related parties [domain]
Key management personnel of entity or parent [member]
Non-Executive Director [member]
Associates [axis]
Associates [domain]
Roche Holding AG [member]
Products and services [axis]
Products and services [domain]
Lucentis [member]
Xolair [member]
Proportion of voting rights held in associate
Net expense, royalties cost sharing and profit sharing
Key management personnel compensation, post-employment benefits
Key management personnel compensation, share-based payment
Key management personnel compensation
Post-employment benefits
Equity-based compensation
Total
Genentech, Inc., USA [member]
Prof. Dr. Brody [member]
Prof. Dr. Zinkernagel [member]
Dr. Alex Krauer [member]
Dr. Daniel Vasella [member]
Dr. James Bradner [member]
Key management personnel compensation, daily rate
Key management personnel compensation, annual guaranteed minimum
Key management personnel compensation, shares acquired
Key management personnel compensation, ownership interest acquired
Changes in consolidated statements of comprehensive income [table]
Fair value adjustments on marketable securities [member]
Fair value adjustments on marketable securities
Fair value adjustments on deferred cash flow hedges [member]
Fair value adjustments on deferred cash flow hedges
Actuarial gains/losses from defined benefit plans [member]
Actuarial gains/losses from defined benefit plans
Cumulative currency translation effects [member]
Cumulative currency translation effects
Changes in consolidated statements of comprehensive income [line items]
Value adjustments on comprehensive income at end of period
Net actuarial gains/losses from defined benefit plans, net of taxes
Total value adjustments
Fair value adjustments on financial instruments
Available-for-sale financial investments
Available-for-sale marketable securities
Gain (loss) on sale of marketable investments
Marketable securities sold
Gain (loss) on sale of other financial assets
Other financial assets sold
Fair value adjustments during the year
Remeasurements from defined benefit plans [line items]
Disclosure of reconciliation of changes in intangible assets and goodwill [table]
Classes of intangible assets and goodwill [axis]
Goodwill [member]
Intangible Assets other than Goodwill
Goodwill
Currently marketed products
Marketing know-how
Disclosure of detailed information about intangible assets [line items]
Intangible assets and goodwill
Intangible assets and goodwill at beginning of period
Intangible assets and goodwill at end of period
Acquisitions through business combinations, intangible assets and goodwill
Impact of business combinations
Increase (decrease) through transfers, intangible assets and goodwill
Reclassifications
Additions other than through business combinations, intangible assets other than goodwill
Additions
Disposals and retirements, intangible assets and goodwill
Disposals and derecognitions
Increase (decrease) through net exchange differences, intangible assets and goodwill
Currency translation effects
Amortisation, intangible assets other than goodwill
Amortization charge
Impairment loss recognised in profit or loss, intangible assets and goodwill
Impairment charge
Reversal of impairment loss recognised in profit or loss, intangible assets other than goodwill
Reversal of impairment charge
Net book value
Segment consolidation items [axis]
Segment consolidation items [domain]
Operating segments [member]
Innovative Medicines [member]
Innovative Medicines
Sandoz [member]
Sandoz
Alcon [member]
Alcon
Unallocated amounts [member]
Growth rate used to extrapolate cash flow projections
Terminal Growth Rate
Discount rate used in current measurement of fair value less costs of disposal
Discount Rate (post-tax)
Impairment loss recognised in profit or loss, intangible assets other than goodwill
Intangible asset impairment charges
Description of justification for using growth rate that exceeds long-term average growth rate
Description of growth rate
Disclosure of terms and conditions of share-based payment arrangement [table]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Types of share-based payment arrangements [axis]
Types of share-based payment arrangements [domain]
Equity-Based Participation Annual Incentive Plan [member]
Equity-Based Participation Share Savings Plan [member]
Equity-Based Participation Leveraged Share Savings Plan [member]
Equity-Based Participation Employee Share Ownership Plan [member]
Equity-Based Participation UK Share Savings Plan [member]
Equity-Based Participation Novartis Equity Plan "Select" [member]
Equity-Based Participation Long-Term Performance Plan [member]
Equity-Based Participation Long Term Relative Performance Plan [member]
Equity-Based Participation Special Share Awards [member]
Description of share-based payment arrangement
Description of method of settlement for share-based payment arrangement
Description of vesting requirements for share-based payment arrangement
Liabilities from share-based payment transactions
Disclosure of number and weighted average remaining contractual life of outstanding share options [table]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number of share options outstanding in share-based payment arrangement
Number of share options outstanding at beginning of period
Number of share options outstanding at end of period
Disclosure of number and weighted average exercise prices of share options [roll forward]
Number of share options exercised in share-based payment arrangement
Number of share options forfeited in share-based payment arrangement
Number of share options exercisable in share-based payment arrangement
Number of share options exercised or sold
Number of share options forfeited or expired
Number of share options exercisable
Disclosure of number and weighted average remaining contractual life of outstanding share options [abstract]
Ranges of exercise prices for outstanding share options [axis]
Ranges of exercise prices for outstanding share options [domain]
Equity-Based Participation Restricted Shares [member]
Remeasurements from defined benefit plans, total after tax
Other comprehensive income, before taxes, gains (losses) on remeasurements of defined benefit plans
Defined benefit pension plans before tax
Other comprehensive income, before taxes, gains (losses) on remeasurements of other post-employment benefit plans
Other post-employment benefit plans before tax
Other comprehensive income, gains (losses) on remeasurements of defined and other post-employment benefit plans, taxation
Taxation on above items
Key management personnel compensation, shares acquired, price
Value adjustment on comprehensive income
Value adjustments on comprehensive income at beginning of period
Gains (losses) on value adjustment on comprehensive income
Total value adjustments attributable to Novartis shareholders [Member]
Total value adjustments
Alcon, Inc., equity plan, converted, Novartis share options [member]
Alcon, Inc., equity plan, converted, Share-settled appreciation rights (SSAR) [member]
Number of share options exercised
Schedule of unvested restricted stock units roll forward [table]
Annual incentive
Share savings plans
Select
Long-Term Performance Plan
Long-Term Relative Performance Plan
Special share awards
Fair value at grante date at end of period
Vested, fair value at grante date
Forfeited, fair value at grante date
Granted, fair value at grante date
Disclosure of operating segments [abstract]
Disclosure of operating segments [table]
Disclosure of operating segments [line items]
Material reconciling items [member]
Revenue from sale of goods, sales to other segments
Sales to discontinued operations
Interest income
Depreciation and amortisation expense
Total liabilities
Net operating assets
Net operating assets
Purchase of interests in associates
Additions to investment in associated companies
Cash and cash equivalents, marketable securities, commodities, time deposits and derivative financial instruments
Current income tax liabilities and deferred tax liabilities
Net sales (in % of total net sales)
Total of selected non-current assets
Total of property, plant and equipment; goodwill; intangible assets; and investment in associated companies
Total of property, plant and equipment; goodwill; intangible assets; and investment in associated companies. As percent of total selected non-current assets.
Other
Other countries [member]
Asia/Africa/Australasia [member]
Percentage of entity's revenue
Disclosure of major customers [abstract]
Disclosure of major customers [table]
Disclosure of major customers [line items]
Major customers [axis]
Major customers [domain]
Largest customer [member]
Second largest customer [member]
Third largest customer [member]
Disclosure of entity's operating segments [text block]
Operating segment
Disclosure of operating segments [text block]
Segmentation - Consolidated income statements
Disclosure of operating segments, balance sheet [table text block]
Segmentation - Consolidated balance sheets
Net sales by core therapeutic area and established brands
Disclosure of associates [abstract]
Disclosure of investments accounted for using equity method [text block]
Associated companies
Disclosure of associates [text block]
Schedule disclosing information related to associates
Disclosure of associates balance sheet [table text block]
Schedule disclosing information related to associates, balance sheet value
Associates summarized financial information [table text block]
Purchase price allocation associates [table text block]
Disclosure of associates [table]
Disclosure of associates [line items]
Roche Holding AG, Switzerland
GlaxoSmithKline Consumer Healthcare Holdings Ltd., UK
GlaxoSmithKline Consumer Healthcare Holdings Ltd. [member]
Others associates [member]
Others
Share of total comprehensive income of associates and joint ventures accounted for using equity method
Total comprehensive income effect
Balance sheet value
Proportion of ownership interest in associate
Dividends received
Revaluation increase (decrease), intangible assets other than goodwil
Novartis share of re-appraised intangible assets
Share of estimated net assets
Novartis share of estimated net assets
Current value of share in net identifiable assets and goodwill
Accumulated equity accounting adjustments and translation effects less dividends received
Consolidated income statement effects [table]
Novartis share of current year consolidated net income
Prior year adjustment
Amortization of fair value adjustments relating to intangible assets
Taxes on Amortization of fair value adjustments relating to intangible assets
Disclosure of detailed information about provisions and non-current liabilities [abstract]
Disclosure of other provisions, contingent liabilities and contingent assets [text block]
Provisions and other non-current liabilities
Disclosure of other provisions [text block]
Environmental remediation provisions, fiscal year maturity [table text block]
Product liability governmental investigations other legal matters provision movements [table text block]
Disclosure of other provisions [table]
Disclosure of other provisions [line items]
Non-current net defined benefit liability
Defined benefit pension plans
Other long-term employee benefits and deferred compensation
Other post-employment benefits
Environmental remediation provisions, non-current
Contingent consideration
Environmental provision [roll forward]
Cash payments
Releases of provisions
Additions to provisions
Currency translation effects
Less current provision
Environmental provision, fiscal year maturity [abstract]
Total environmental remediation liability provisions
Due within two years
Due later than two years, but within five years
Due later than five years, but within ten years
Due after ten years
Product liability, government investigations, other legal matters provisions [roll forward]
Provisions related to discontinued operations
Cash payments
Releases of provisions
Additions to provisions
Currency translation effects
Product liabilities government investigations other legal matters provisions at end of period
Less current provision
Non-current product liabilities, governmental investigations and other legal matters provisions at end of period
Legal proceedings provision [member]
Solodyn [member]
Contact Lenses [member]
Gleevec [member]
Reclast/Aclasta [member]
Tekturna/Rasilez/Valturna [member]
NAG and Novartis Pharma SpA [member]
F Hoffman La Roche AG and Roche SpA [member]
Novartis Pharma K.K. [member]
NAG [member]
NPC and others [member]
Novartis NC [member]
Product liability contingency, loss exposure not accrued, number of cases
Estimated financial effect of contingent liabilities
Description of nature of obligation contingent liabilities, number of legal questions referred to court
Estimated financial effect of contingent liabilities, maximum fine
Description of nature of obligation contingent liabilities, number of putative cases referred to court
Description of nature of obligation contingent liabilities, number of other cases referred to court
Description of nature of obligation contingent liabilities, number of states with alleged violations
Description of nature of obligation contingent liabilities, number of cases still pending
Revenue
1.800% USD 1'000 million 2017/2020 of Novartis Capital Corporation, New York, United States, issued at 99.609% [member]
2.400% USD 1'000 million 2017/2022 of Novartis Capital Corporation, New York, United States, issued at 99.449% [member]
3.100% USD 1'000 million 2017/2027 of Novartis Capital Corporation, New York, United States, issued at 99.109% [member]
0.000% EUR 1'250 million 2017/2021 of Novartis Finance S.A., Luxembourg, Luxembourg, issued at 99.133% [member]
1.125% EUR 600 million 2017/2027 of Novartis Finance S.A., Luxembourg, Luxembourg, issued at 99.874% [member]
Transactions with former members of the Board of Directors [table text block]
Transactions with former members of the Board of Directors
Total fair value adjustments [member]
Total fair value adjustments
Provisions at beginning of period
Provisions at end of period
Disclosure of maturity analysis for non-derivative financial liabilities [abstract]
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Disclosure of maturity analysis for non-derivative financial liabilities [table]
Later than one month and not later than three months [member]
Later than one year [member]
Later than six months and not later than one year [member]
Later than three months and not later than six months [member]
Not later than one month [member]
Other non-current liabilities
Past service cost and gains losses arising from settlements, net defined benefit liability (asset)
Past service cost and settlements
Tax rate, effect from change in tax rate
Effect of tax rate change on current and deferred tax assets and liabilities
Tax rate, effect of expense not deductible in determining taxable profit tax loss
Effect of disallowed expenditures
Tax rate, effect of tax losses
Effect of utilization of tax losses brought forward from prior periods
Other expense
Other expense, by function
Par value per share
Other current assets
Marketable securities, time deposits and derivative financial instruments
Total marketable securities, time deposits and derivative financial instruments
Taxotere [member]
Amiodarone [member]
Disclosure of equity [abstract]
Disclosure of equity [text block]
Equity
Dividend [table text block]
Schedule disclosing information related to Dividend
Amendment Flag
Document Period End Date
Document Fiscal Year Focus
Document Fiscal Period Focus
Trading Symbol
Entity Registrant Name
Entity Central Index Key
Current Fiscal Year End Date
Entity Well-known Seasoned Issuer
Entity Current Reporting Status
Entity Voluntary Filers
Entity Filer Category
Entity Common Stock, Shares Outstanding
Entity Public Float
UNITED STATES
UNITED KINGDOM
GERMANY
FRANCE
JAPAN
US
UK
Germany
France
Japan
ITALY
Italy
CANADA
Canada
United States of America, Dollars
USD
Euro Member Countries, Euro
EUR
Japan, Yen
JPY
China, Yuan Renminbi
CNY
United Kingdom, Pounds
GBP
CHF
Document Information [Table]
Document Information [Line Items]
Legal Entity [Axis]
Entity [Domain]
All Currencies [Domain]
Need new ITEM here
General and Administration
Increase (decrease) in non-controling interests
Changes in non-controlling interests
Dividends received from associated companies and others
Dividends received, classified as operating activities
Finance income received, classified as operating activities
Other financial receipts
Finance costs paid, classified as operating activities
Other financial payments
Proceeds from sales of interests in associates
Acquisitions and divestments of interests in associated companies, net
Dividends paid to shareholders of Novartis AG
Dividends paid to equity holders of parent, classified as financing activities
Proceeds from non-current financial debts
Repayments of non-current borrowings
Repayments of non-current financial debts
Proceeds from non-current borrowings
Cash flows from (used in) increase (decrease) in current borrowings
Change in current financial debts
Other financing cash flows, net
Other inflows (outflows) of cash, classified as financing activities
Income taxes paid (refund)
Income taxes paid (refund), classified as investing activities
Number of Reportable Segments
Number of Business Units
Number of Franchises
Additions to property, plant and equipment
Additions to intangible assets and goodwill
Revenue from sale of goods third parties
Net sales to third parties
Revenue from sale of goods, as percent of total net sales
Selected non-current assets, as percent
Selected non-current assets (in % of total selected non-current assets)
Fair value of investments in associates for which there are quoted market prices
Investments in subsidiaries, joint ventures and associates
Interest expense, gross
Other financial income
Impairment loss on commodities and available-for-sale securities, net
Impairment of commodities and available-for-sale securities, net
Other finance cost
Financial expense
Tax expense (income), discontinuing operations
Income tax expense from discontinued operations
Tax rate, effect from non-deductible losses
Effective income tax rate reconciliation change in uncertain tax positions
Other comprehensive income net of tax gains/losses on remeasurements of defined benefit plans related to discontinued operations
Other comprehensive income net of tax exchange differences on translation related to discontinued operations
Brands [axis]
Brands [member]
Established Brands [member]
Promoted Brands [member]
Core therapeutic area and established brands [axis]
Core therapeutic area and established brands [member]
Ophthalmology [member]
Neuroscience [member]
Respiratory and Allergy [member]
Cardiovascular, renal and metabolic [member]
Established Medicines [member]
Product portfolio [axis]
Product portfolio [member]
COPD [member]
Gleevec/Glivec [member]
Tasigna [member]
Sandostatin Group [member]
Afinitor/Votubia [member]
Exjade/Jadenu [member]
Tafinlar + Mekinist [member]
Promacta/Revolade [member]
Votrient [member]
Jakavi [member]
Kisqali [member]
Other [member]
Travoprost Group [member]
Systane Group [member]
Topical Olopatadine Group [member]
Cosentyx [member]
Neoral/Sandimmun(e) [member]
Zortress/Certican [member]
Ilaris [member]
Myfortic [member]
Gilenya [member]
Ultibro Breezhaler [member]
Seebri Breezhaler [member]
Onbrez Breezhaler [member]
Entresto [member]
Galvus Group [member]
Exforge Group [member]
Diovan Group [member]
Voltaren/Cataflam [member]
Exelon/Exelon Patch [member]
Ritalin/Focalin [member]
Accumulated depreciation on disposals, property plant and equipment
Accumulated depreciation on disposals and derecognitions
Accumulated impairments on disposals and derecognition
Acquired research and development [member]
Acquired research and development
Alcon brand name [member]
Alcon brand name
Gross value of tax loss carry forwards expiring in future years
Net sales, change in %
Shareholders of Novartis AG
Cumulative currency translation gains/losses recycled through income statement
Impaired loss on financial assets transferred to the income statement
Reclassification adjustments on financial assets measured at fair value through other comprehensive income, net of tax
Other comprehensive income, available-for-sale financial investments
Other comprehensive income, maketable securities
Available-for-sale marketable securities
Net book value
Finance lease receivables
Minimum lease payments from finance lease agreements
Provision for doubtful receivable [member]
Outstanding share capital
Total outstanding share capital at beginning of period
Total outstanding share capital at end of period
Treasury shares movement of period
Issued capital, movement
Share capital movement of period
Outstanding share capital, movement
Total shares outstanding movement of period
Shares cancelled for capital reduction
Treasury shares, movement
Total number of outstanding treasury shares
Purchase of treasury shares
Purchase of treasury shares, equity impact
Equity impact of treasury share movements
Total equity impact of treasury share movements
Average interest rate on loans received
Ratio fixed rate financial debt to total financial debt
Average interest rate on borrowings
Borrowings, coupon
Borrowings, issuance year
Borrowings, maturity year
Borrowings, issuer
Borrowings, issue price
Environmental remediation provisions
Accrual for environmental loss contingencies
Environmental liabilities provision at beginning of period
Environmental liabilities provision at end of period
Accrual for environmental loss contingencies, payments
Accrual for environmental loss contingencies, releases
Accrual for environmental loss contingencies, additions
Accrual for environmental loss contingencies, foreign currency translation gain (loss)
Accrual for environmental loss contingencies, Current
Non-current environmental remediation provisions at end of period
Environmental provision, expected cash outflow, next two years
Environmental provision, expected cash outflow, later than two years, but within five years
Environmental provision, expected cash outflow, later than five years, but within ten years
Environmental provision, expected cash outflow, after ten years
Product liability, government investigations, other legal matters provisions
Product liabilities government investigations other legal matters provisions at beginning of period
Product liability, government investigations, other legal matters provisions, discontinued operations
Product liability, government investigations, other legal matters provisions, payments
Product liability, government investigations, other legal matters provisions, releases
Product liability, government investigations, other legal matters provisions, additions
Product liability, government investigations, other legal matters provisions, foreign currency translation gain (loss)
Product liability, government investigations, other legal matters provisions, current
Product liability, government investigations, other legal matters provisions, non-current
Provisions for product liability, government investigations, other legal matters provisions
Weighted average interest rate on interest bearning accounts of associates payable on demand.
Weighted average interest rate on Bank and other financial debt
Weighted average interest rate on Bank and other financial debt
Environmental remediation provisions
Accrued expenses
Accruals classified as current
Contingent consideration, current portion
Contingent consideration
Provision for deduction from revenue [table]
Restructuring provisions movements [table]
Restructuring provision transfers
Transfers
Reclassification adjustments on cash flow hedges, net of tax
Amortized net losses on cash flow hedges transferred to the consolidated income statement
Trade and other payables and deferred tax liabilities recognised as of acquisition date
Payables and other liabilities including deferred tax liabilities
Property plant and equipment recognised as of acquisition divestment date
Property, plant and equipment
Currently marketed products intangible assets recognised as of acquisition divestment date
Currently marketed products
Acquired divested research and development intangible assets recognised as of acquisition divestment date
(Acquired)/divested research and development
Technologies recognised as of acquisition divestment date
Technologies
Other intangible assets recognised as of acquisition divestment date
Other intangible assets
Financial and other assets including deferred tax assets recognised as of acquisition divestment date
Financial and other assets including deferred tax assets
Inventory recognised as of acquisition divestment date
Inventories
Trade receivables and other current assets recognised as of acquisition divestment date
Trade receivables and other current assets
Cash and cash equivalents recognised as of acquisition divestment date
Cash and cash equivalents
Current and non-current financial debts recognised as of acquisition divestment date
Current and non-current financial debts
Trade and other payables recognised as of acquisition divestment date
Trade payables and other liabilities including deferred tax liabilities
Animal health [member]
Proceeds from sale of business
Cash flows used in/from investing activities from discontinued operations
Financial debts, derivative financial instruments and lease liabilities at end of period
Changes in fair values, lease interest and other changes, net
Amortization of bonds discount
Current portion of non-current financial debt
Genentech / Roche [member]
Number of contracts with related parties
Executive Committee members
Related parties, number of non-executive directors
Non-executive directors
Defined benefit plan, foreign currency exchange rate gain (loss)
Increase (decrease) through changes in foreign exchange rates, defined benefit liability (asset)
Later than five years and not later than ten years [member]
Disclosure of financial assets [table]
Disclosure of financial assets [line items]
Financial assets
Classes of financial assets [axis]
Classes of financial assets [domain]
Financial assets at amortised cost, class [member]
Cash and cash equivalents [member]
Categories of financial assets [axis]
Categories of financial assets [domain]
Available-for-sale marketable securities [member]
Balance sheet item [axis]
Balance sheet item [member]
Equity securities [member]
Fund investments [member]
Trade receivables and other current assets excluding pre-payments [member]
Current contingent consideration receivables [member]
Accrued interest on debt securities and time deposits [member]
Time deposits with original maturity more than 90 days [member]
Long-term loans and receivables from customers and finance lease, advances, security deposits [member]
Associated companies at fair value through profit and loss [member]
Derivative financial instruments [member]
Disclosure of financial liabilities [table]
Classes of financial liabilities [axis]
Classes of financial liabilities [domain]
Financial liabilities at amortised cost, class [member]
Financial liabilities at fair value, class [member]
Groups of financial assets/liabilities [axis]
Groups of financial assets/liabilities [member]
Financial assets at fair value, class [member]
Financial assets at fair value through profit or loss, category [member]
Financial assets at fair value through other comprehensive income, category [member]
Categories of financial liabilities [domain]
Categories of financial liabilities [axis]
Financial liabilities at fair value through profit or loss, category [member]
Financial liabilities at amortised cost, category [member]
Financial assets at amortised cost, category [member]
Current financial debt [member]
Non-current financial debt [member]
Trade payables [member]
Interest bearning accounts of associates payable on demand [member]
Bank and other financial debt [member]
Commercial paper [member]
Current portion of non-current debt [member]
Straight bonds [member]
Liabilities to banks and other financial institutions [member]
Finance lease obligations [member]
Contingent consideration and other financial liabilities [member]
Disclosure of derivative financial instruments, by type of contract [table]
Derivative financial instrument, nature of instrument [axis]
Derivative financial instrument, nature of instrument [member]
Derivative financial instruments, at fair value currency related [member]
Financial instruments, principal amounts [axis]
Financial instruments, principal amounts [member]
Contract or underlying principal amout [member]
Positive fair values [member]
Negative fair values [member]
Disclosure of fair value measurement [line items]
Disclosure of financial liabilities [line items]
Financial liabilities
Derivative financial instruments
Derivative financial instruments, forward foreign exchange rate contracts
Derivative financial instruments, over-the-counter currency options
Disclosure of derivative financial instruments, by currency contract [table]
Disclosure of fair value measurement of assets [table]
Measurement [axis]
Measurement [domain]
Recurring fair value measurement [member]
Marketable securities and derivative financial instruments [member]
Long- term financial investments at fair value [member]
Total available-for-sale marketable securities [member]
Available-for-sale financial investments [member]
Disclosure of fair value measurement of assets [line items]
Valued at amortized cost [member]
Classes of liabilities [axis]
Classes of liabilities [domain]
Contingent consideration liabilities [member]
Other financial liabilities [member]
China Novartis Institutes for BioMedical Research Co., Ltd., Shanghai [member]
Dividends proposed, cash per share
Dividends proposed or declared before financial statements authorised for issue but not recognised as distribution to owners per share
Dividends proposed
Increase/decrease in fair value measurement liabilities
Financial assets, at fair value
Financial liabilities, at fair value
Other comprehensive income, net of tax, hedges of net investments in foreign operations
Net investment hedge, net of taxes
Novartis Australia Pty Ltd, Macquarie Park, NSW [member]
Novartis Pharmaceuticals Australia Pty Ltd, Macquarie Park, NSW [member]
Alcon Laboratories (Australia) Pty Ltd, Macquarie Park, NSW [member]
Sandoz Pty Ltd, Macquarie Park, NSW [member]
Novartis Austria GmbH, Vienna [member]
Novartis Pharma GmbH, Vienna [member]
Alcon Ophthalmika GmbH, Vienna [member]
Sandoz GmbH, Kundl [member]
EBEWE Pharma Ges.m.b.H Nfg. KG, Unterach am Attersee [member]
Novartis (Bangladesh) Limited, Gazipur [member]
Novartis Pharma NV, Vilvoorde [member]
Novartis Manufacturing NV, Puurs-Sint-Amands [member]
Alcon NV, Vilvoorde [member]
Sandoz NV, Vilvoorde [member]
Novartis Securities Investment Ltd., Hamilton [member]
Novartis Biociencias S.A., Sao Paulo [member]
Sandoz do Brasil Industria Farmaceutica Ltda., Cambe, PR [member]
Novartis Pharmaceuticals Canada Inc., Dorval, Quebec [member]
Alcon Canada Inc., Mississauga, Ontario [member]
CIBA Vision Canada Inc., Mississauga, Ontario [member]
Sandoz Canada Inc., Boucherville, Quebec [member]
Novartis Chile S.A., Santiago de Chile [member]
Alcon Laboratorios Chile Ltd., Santiago de Chile [member]
Beijing Novartis Pharma Co., Ltd., Beijing [member]
Novartis Pharmaceuticals (HK) Limited, Hong Kong [member]
Suzhou Novartis Pharma Technology Co., Ltd., Changshu [member]
Shanghai Novartis Trading Ltd., Shanghai [member]
Alcon Hong Kong Limited, Hong Kong [member]
Alcon (China) Ophthalmic Product Co., Ltd., Beijing [member]
Sandoz (China) Pharmaceutical Co., Ltd., Zhongshan [member]
Novartis de Colombia S.A., Santafe de Bogota [member]
Laboratorios Alcon de Colombia S.A., Santafe de Bogota [member]
Sandoz d.o.o. farmaceutska industrija, Zagreb [member]
Novartis s.r.o., Prague [member]
Alcon Pharmaceuticals (Czech Republic) s.r.o., Prague [member]
Sandoz s.r.o., Prague [member]
Novartis Healthcare A/S, Copenhagen [member]
Alcon Nordic A/S, Copenhagen [member]
Sandoz A/S, Copenhagen [member]
Novartis Ecuador S.A., Quito [member]
Novartis Pharma S.A.E., Cairo [member]
Sandoz Egypt Pharma S.A.E., New Cairo City [member]
Novartis Finland Oy, Espoo [member]
Novartis Groupe France S.A., Rueil-Malmaison [member]
Novartis Pharma S.A.S., Rueil-Malmaison [member]
Laboratoires Alcon S.A.S., Rueil-Malmaison [member]
Sandoz S.A.S., Levallois-Perret [member]
Novartis Deutschland GmbH, Wehr [member]
Novartis Pharma GmbH, Nuremberg [member]
Novartis Pharma Produktions GmbH, Wehr [member]
Novartis Business Services GmbH, Nuremberg [member]
Alcon Pharma GmbH, Freiburg im Breisgau [member]
WaveLight GmbH, Erlangen [member]
CIBA Vision GmbH, Grosswallstadt [member]
Sandoz International GmbH, Holzkirchen [member]
HEXAL AG, Holzkirchen [member]
Salutas Pharma GmbH, Barleben [member]
1 A Pharma GmbH, Holzkirchen [member]
Aeropharm GmbH, Rudolstadt [member]
Novista Insurance Limited, Gibraltar City [member]
Novartis (Hellas) S.A.C.I., Metamorphosis/Athens [member]
Alcon Laboratories Hellas Commercial and Industrial S.A., Maroussi, Athens [member]
Novartis Hungary Healthcare Limited Liability Company, Budapest [member]
Sandoz Hungary Limited Liability Company, Budapest [member]
Novartis India Limited, Mumbai [member]
Novartis Healthcare Private Limited, Mumbai [member]
Alcon Laboratories (India) Private Limited, Bangalore [member]
Sandoz Private Limited, Mumbai [member]
PT. Novartis Indonesia, Jakarta [member]
PT. CIBA Vision Batam, Batam [member]
Novartis Ireland Limited, Dublin [member]
Novartis Ringaskiddy Limited, Ringaskiddy, County Cork [member]
Alcon Laboratories Ireland Limited, Cork City [member]
Novartis Israel Ltd., Tel Aviv [member]
Optonol Ltd., Neve-Ilan [member]
Novartis Farma S.p.A., Milan [member]
Alcon Italia S.p.A., Milan [member]
Sandoz S.p.A., Origgio [member]
Sandoz Industrial Products S.p.A., Rovereto [member]
Novartis Holding Japan K.K., Tokyo [member]
Novartis Pharma K.K., Tokyo [member]
Alcon Japan Ltd., Tokyo [member]
Sandoz K.K., Tokyo [member]
Novartis Investments S.a r.l., Howald [member]
Novartis Finance S.A., Howald [member]
Novartis Corporation (Malaysia) Sdn. Bhd., Petaling Jaya [member]
Alcon Laboratories (Malaysia) Sdn. Bhd., Petaling Jaya [member]
CIBA Vision Johor Sdn. Bhd., Kuala Lumpur [member]
Novartis Farmaceutica, S.A. de C.V., Mexico City [member]
Alcon Laboratorios, S.A. de C.V., Mexico City [member]
Sandoz, S.A. de C.V., Mexico City [member]
Novartis Pharma Maroc SA, Casablanca [member]
Novartis Netherlands B.V., Arnhem [member]
Novartis Pharma B.V., Arnhem [member]
Alcon Nederland B.V., Arnhem [member]
Sandoz B.V., Almere [member]
Novartis New Zealand Ltd, Auckland [member]
Novartis Norge AS, Oslo [member]
Novartis Pharma (Pakistan) Limited, Karachi [member]
Novartis Pharma (Logistics), Inc., Panama City [member]
Alcon Centroamerica S.A., Panama City [member]
Novartis Healthcare Philippines, Inc., Makati City [member]
Sandoz Philippines Corporation, Makati City [member]
Novartis Poland Sp. z o.o., Warsaw [member]
Alcon Polska Sp. z o.o., Warsaw [member]
Sandoz Polska Sp. z o.o., Warsaw [member]
Lek S.A., Strykow [member]
Novartis Portugal SGPS Lda., Porto Salvo [member]
Novartis Farma - Produtos Farmaceuticos S.A., Porto Salvo [member]
Alcon Portugal-Produtos e Equipamentos Oftalmologicos Lda., Porto Salvo [member]
Sandoz Farmaceutica Lda., Porto Salvo [member]
Novartis Pharma Services Romania S.R.L., Bucharest [member]
Alcon Romania S.R.L., Bucharest [member]
Novartis Pharmaceuticals S.R.L., Targu-Mures [member]
Novartis Pharma LLC, Moscow [member]
Alcon Farmacevtika LLC, Moscow [member]
JSC Sandoz, Moscow [member]
Novartis Neva LLC, St. Petersburg [member]
Saudi Pharmaceutical Distribution Co. Ltd., Riyadh [member]
Novartis (Singapore) Pte Ltd., Singapore [member]
Novartis Singapore Pharmaceutical Manufacturing Pte Ltd, Singapore [member]
Novartis Asia Pacific Pharmaceuticals Pte Ltd, Singapore [member]
Novartis Institute for Tropical Diseases Pte Ltd, Singapore [member]
Alcon Singapore Manufacturing Pte. Ltd., Singapore [member]
CIBA Vision Asian Manufacturing and Logistics Pte Ltd., Singapore [member]
Alcon Pte Ltd, Singapore [member]
Novartis Slovakia s.r.o., Bratislava [member]
Lek Pharmaceuticals d.d., Ljubjana [member]
Sandoz Pharmaceuticals d.d., Ljubjana [member]
Novartis South Africa (Pty) Ltd, Midrand [member]
Alcon Laboratories (South Africa) (Pty) Ltd., Midrand [member]
Sandoz South Africa (Pty) Ltd, Midrand [member]
Novartis Korea Ltd., Seoul [member]
Alcon Korea Ltd., Seoul [member]
Sandoz Korea Ltd., Seoul [member]
Novartis Farmaceutica, S.A., Barcelona [member]
Alcon Cusi S.A., Barcelona [member]
Sandoz Farmaceutica S.A., Madrid [member]
Sandoz Industrial Products S.A., Les Franqueses del Valles / Barcelona [member]
Abadia Retuerta S.A., Sardon de Duero/Valladolid [member]
Novartis Sverige AB, Stockholm [member]
Novartis International AG, Basel [member]
Novartis Holding AG, Basel [member]
Novartis International Pharmaceutical AG, Basel [member]
Novartis Pharma AG, Basel [member]
Novartis Pharma Services AG, Basel [member]
Novartis Pharma Schweizerhalle AG, Muttenz [member]
Novartis Pharma Stein AG, Stein [member]
Novartis Pharma Schweiz AG, Risch [member]
Alcon Switzerland SA, Risch [member]
Alcon Pharmaceuticals Ltd., Fribourg [member]
Sandoz AG, Basel [member]
Sandoz Pharmaceuticals AG, Risch [member]
Novartis (Taiwan) Co., Ltd., Taipei [member]
Novartis (Thailand) Limited, Bangkok [member]
Alcon Laboratories (Thailand) Limited, Bangkok [member]
Novartis Saglik, Gida ve Tarim Urunleri Sanayi ve Ticaret A.S., Istanbul [member]
Alcon Laboratuvarlari Ticaret A.S., Istanbul [member]
Sandoz Ilac Sanayi ve Ticaret A.S., Istanbul [member]
Sandoz Grup Saglik Urunleri Ilaclari Sanayi ve Ticaret A.S., Gebze - Kocaeli [member]
Novartis Middle East FZE, Dubai [member]
Novartis UK Limited, Frimley/Camberley [member]
Novartis Pharmaceuticals UK Limited, Frimley/Camberley [member]
Novartis Grimsby Limited, Frimley/Camberley [member]
Alcon Eye Care UK Limited, Frimley/Camberley [member]
Sandoz Limited, Frimley/Camberley [member]
Glaxosmithkline Consumer Healthcare Holdings Limited, Brentford, Middlesex [member]
Novartis Corporation, East Hanover, NJ [member]
Novartis Finance Corporation, New York, NY [member]
Novartis Capital Corporation, New York, NY [member]
Novartis Pharmaceuticals Corporation, East Hanover, NJ [member]
Novartis Institutes for BioMedical Research, Inc., Cambridge, MA [member]
Novartis Institute for Functional Genomics, Inc., San Diego, CA [member]
Novartis Vaccines and Diagnostics, Inc., Cambridge, MA [member]
Novartis Services, Inc., East Hanover, NJ [member]
Alcon Laboratories Holding Corporation, Fort Worth, TX [member]
Alcon Laboratories, Inc., Fort Worth, TX [member]
Alcon Refractivehorizons, LLC, Fort Worth, TX [member]
Alcon Research, Ltd., Fort Worth, TX [member]
Alcon Lensx, Inc., Aliso Viejo, CA [member]
Sandoz Inc., Princeton, NJ [member]
Eon Labs, Inc., Princeton, NJ [member]
Fougera Pharmaceuticals Inc., Melville, NY [member]
Novartis de Venezuela, S.A., Caracas [member]
Alcon Pharmaceutical, C.A., Caracas [member]
Financial Instruments - additional disclosure [abstract]
Reconciliation of changes in fair value measurement [table]
Fair value measurement, carrying value, level 3
Fair value measurement, carrying value, level 3, at beginning of period
Fair value measurement, carrying value, level 3, at end of period
Fair value gains and other adjustments including from divestments recognized in the consolidated income statement
Fair value losses (including impairments and amortizations) and other adjustments recognized in the consolidated income statement
Fair value adjustments recognized in the consolidated statement of comprehensive income
Purchases fair value measurement assets
Disposals fair value measurement assets
Reclassification fair value measurement assets
Fair value gains and losses recognized in the consolidated income statement for assets and liabilities held
Total fair value gains and (losses) recognized in the consolidated income statement for assets and liabilities held at period end
Monitoring of net debt or liquidity based on contractual maturities [table]
Maturity of net debt [line items]
Non-current financial debts
Current financial debt
Current financial assets
Marketable securities, time deposits and short-term investments with original maturity more than 90 days and accrued interest [member]
Commodities [member]
Deriviative financial instruments [member]
Financial debt [member]
Financial debt - undiscounted [member]
Later than three month and not later than twelve months [member]
Derivative financial instruments and accrued interest on derivative financial instruments [line items]
Potential outflows in various currencies - from financial derivative liabilities
Potential inflows in various currencies - from financial derivative assets
Derivative financial instruments and accrued interest on derivative financial instruments [table]
Contractual interest on non-current financial debt, including current portion
Ten day loss fair value VAR model [table]
Ten day loss fair value VAR model [line items]
Financial instruments, value at risk computation
Financial instruments, value at risk computation, sensitive to foreign currency exchange rates
Financial instruments, value at risk computation, sensitive to equity market movements
Financial instruments, value at risk computation, sensitive to interest rates
All financial instruments
Instruments sensitive to foreign currency exchange rates
Instruments sensitive to equity market movements
Instruments sensitive to interest rates
Weighted average [member]
Average
High
Low
Worst case loss scenario [member]
Worst case loss scenario
Cash receipts and payments fair value measurement assets
Potential outflows in various currencies - from financial derivative liabilities
Deferred tax liabilities
Total liabilities
Net deferred tax balance
Reversal of provisions for doubtful trade receivables
Publicly quoted market value of the Novartis interest
Current service cost
Net interest expense
Equity-Based Participation Novartis Equity Plan "Select", outside North America [member]
Select outside North America
Equity-Based Participation Novartis Equity Plan "Select", North America [member]
Select North America
Alcon, Inc., equity plans, granted to associates prior merger [member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares
Forfeited, number of shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Outstanding, Number
Vested, number of shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Granted, Number of Shares
Granted, number of shares
Number of shares at end of period
Number of shares at beginning of period
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares
Loss from associated companies
Equity-Based Participation Other Share Awards [member]
Other share awards
Alcon equity plans granted to associates prior merger
Restricted Shares
Leveraged Share Savings Plan (LSSP)
Employee Share Ownership Plan (ESOP)
UK Share Savings Plan
Provisions for product liabilities, governmental investigations and other legal matters
Share movements in period
Total movements
Net expense, royalties cost sharing and profit sharing
Net investment hedge [member]
Written call options held by market maker
Written call options, contractual live
Written call options, contractual live, remaining
Written call options, weighted average exercise price
Total interest expense
Change in current financial debts
Dividends paid to non-controlling interests and other financing cash flows
Payables and other liabilities including deferred tax liabilities
Income taxes paid
Taxes paid and other portfolio transformation related cash flows
Payments, deferred consideration and other adjustments, net
Deferred portion of sales price
Fair value losses (including impairments and amortizations) and other adjustments recognized in the consolidated income statement
Disposals fair value measurement assets
Reversal of non-cash items and other adjustments
Total reversal of non-cash items
Adjustments to reconcile profit (loss)
Income taxes (paid)/refund
Income taxes (paid)/refund, classified as investing activities
Income taxes refund/(paid), classified as operating activities
Depreciation and amortisation expense
Impairment loss (reversal of impairment loss) recognised in profit or loss
Impairment charges and fair value gains on financial assets, net
Equity-based compensation of Novartis equity plans
Net income statement effect
Tax rate, effect of income taxed at reduced rates
Effect of income taxed at reduced rates
Movements of property, plant and equipment [roll forward]
Disposals and derecognitions
Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss
Share-based Compensation Arrangement by Share-based Payment Award, Options, NonVested in Period, Fair Value
Fair value at grante date at beginning of period
Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted in Period, Fair Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeited in Period, Fair Value
Spinifex Pharmaceuticals, Inc., Wilmington, NC [member]
Encore Vision, Inc., New York, NY [member]
Novartis Investment Ltd., Hamilton [member]
Novartis Finance Services Ltd., Hamilton [member]
Novartis B2 Ltd., Hamilton [member]
Novartis B3 Ltd., Hamilton [member]
Ciba-Geigy Japan Limited, Tokyo [member]
Novartis International Pharmaceutical Investment AG, Basel [member]
Novartis Bioventures AG, Basel [member]
Novartis Forschungsstiftung, Basel [member]
Novartis Stiftung fuer Kaderausbildung, Basel [member]
Novartis Mitarbeiterbeteiligungsstiftung, Basel [member]
Novartis Stiftung fuer Mensch und Umwelt, Basel [member]
Stiftung der Novartis AG fuer Erziehung, Ausbildung und Bildung, Basel [member]
Farmanova Saglik Hizmetleri Ltd. Sti., Istanbul [member]
Ziarco Group Limited, Frimley/Camberley [member]
Vivacta Limited, Frimley/Camberley, Surrey [member]
Novartis US Foundation, New York, NY [member]
Corthera, Inc., San Mateo, CA [member]
CoStim Pharmaceuticals Inc., Cambridge, MA [member]
Navigate BioPharma Services, Inc., Carlsbad, CA [member]
Reprixys Pharmaceuticals Corporation, East Hanover, NJ [member]
ClarVista Medical, Inc., Aliso Viejo, CA [member]
Transcend Medical, Inc., Lake Forest, IL [member]
Triangle International Reinsurance Limited, Hamilton [member]
Trinity River Insurance Co Ltd., Hamilton [member]
Sandoz Syntek Ilac Hammaddeleri Sanayi ve Ticaret A.S., Istanbul [member]
Russia, Rubles
RUB
BRL
Brazil, Brazil Real
Australia, Dollars
AUD
CAD
Canada, Dollars
Disclosure of detailed information about financial instruments [text block]
Disclosure of associates, net income effect [table text block]
Schedule disclosing information related to associates, net income effect
Associates summarized financial information
Purchase price allocation associates
Deferred tax assets/liabilities, expected to have impact on current taxes payable
Disclosure of deferred tax assets and liabilities, expected to have impact on current taxes payable [table text block]
Disclosure of unremitted earnings retained by consolidated entities for reinvestment [table text block]
Unremitted earnings retained by consolidated entities for reinvestment
Disclosure of amount of inventory recognized as an expense in cost of goods sold [table text block]
Amount of inventory recognized as an expense in cost of goods sold
Disclosure of recognized amount of inventory provisions and reversals of inventory provision [table text block]
Recognized amount of inventory provisions and reversals of inventory provision
Gross trade receivable from closely monitored countries [table text block]
Gross trade receivable from closely monitored countries
Debt securities, breakdown by currency [table text block]
Debt securities, breakdown by currency
Summary of treasury shares movements [table text block]
Schedule disclosing information related treasury shares movements
US Corporate tax rate, impact on the revaluation of deferred assets and liabilities and current income tax liabilities [text block]
US Corporate tax rate, impact on the revaluation of deferred assets and liabilities and current income tax liabilities
Reconciliation of liabilities arising from financing activities [table text block]
Reconciliation of liabilities arising from financing activities
Schedule of asset allocation, investments in shares of Novartis AG [table text block]
Asset allocation, investments in shares of Novartis AG
Schedule of defined contribution plans [table text block]
Defined contribution plans
Schedule of expense related to all equity-based participation and liabilities arising from equity-based payment transactions [table text block]
Expense related to all equity-based participation and liabilities arising from equity-based payment transactions
Disclosure of financial assets and financial liabilities [table text block]
Disclosure of financial assets and financial liabilities
Disclosure of derivative financial instruments [text block]
Derivative financial instruments
Contract or underlying principal amount the derivative financial instruments, by currency
Disclosure of derivative financial instruments, contract or underlying principal amount the derivative financial instruments, by currency [table text block]
Disclosure of fair value measurement [text block]
Fair value by hierarchy
Disclosure of reconciliation of changes in fair value measurement [table text block]
Reconciliation of changes in fair value measurement
Disclosure of monitoring of net debt or liquidity based on contractual maturities [table text block]
Monitoring of net debt or liquidity based on contractual maturities
Disclosure of derivative financial instruments and accrued interest on derivative financial instruments [table text block]
Derivative financial instruments and accrued interest on derivative financial instruments
Disclosure of other contractual liabilities of the net debt or liquidity [table text block]
Other contractual liabilities of the net debt or liquidity
Disclosure of ten day loss fair value VAR model [table text block]
Ten day loss fair value VAR model
Disclosure of ten day loss fair value VAR model, average, high, and low VAR amounts [table text block]
Ten day loss fair value VAR model, average, high, and low VAR amounts
Disclosure of ten day loss fair value VAR model, worst case loss scenario [table text block]
Ten day loss fair value VAR model, worst case loss scenario
KOREA, REPUBLIC OF
South Korea
Purchase of treasury shares
Impact of change in ownership of consolidated entities
Purchase of treasury shares, equity impact
Payments out of provisions and other net cash movements in non-current liabilities
Portion of consideration paid (received) consisting of cash and cash equivalents
Reprixys Pharmaceuticals Corporation [member]
Reprixys Pharmaceuticals Corporation
Tax rate, effect of release of contingent consideration liability
Effect of release of contingent consideration liability
Income tax expense from continuing operations
Impact of business combinations
Currency translation effects
Deferred tax asset and liability valuation [abstract]
Impact of new tax law deferred tax expense income recognised in profit or loss
Impact of new tax law deferred tax relating to components of other comprehensive income
Impact of new tax law increase decrease in deferred tax liability asset
Impact of new tax law increase decrease in current income tax liability
Impact of new tax law change in deferred tax assets and liabilities and current tax liabilities
Items previously recognized in consolidated income statement
Items previously recognized in other comprehensive income
Total revaluation of deferred tax assets and liabilities
Total revaluation of current income tax liabilities
Total revaluation of deferred tax assets and liabilities and current income tax liabilities
Impact location [axis]
Impact location [member]
Income statement [member]
Increase to retained earnings arising from first application of IFRS 9
Undiscounted operating lease commitments
Contribution of business to joint venture
Effect of income not subject to tax on the divestment gain on GSK investment
Tax benefit arising from previously unrecognised tax loss, tax credit or temporary difference of prior period used to reduce current tax expense
Impact of new tax law income tax relating to available-for-sale financia investments previously recognized through OCI
Impact of new tax law income tax relating to deferred tax assets on US post retirement previously recognized through OCI
Impact of new tax law effective tax rate after implemetation of new law changes
Impact of new tax law tax on unremitted earnings period allowed for payment
Impact of new tax law income tax relating to deferred tax assets on unremitted earnings
Impact of new tax law income tax relating to revaluation of deferred tax assets on equity based compensation that were previously recognized through retained earnings
Acquisitions through finance lease contracts property plant and equipment
Principal group companies materiality of assets or sales to third parties
Other intangible asset purchase commitments
Research and Development and other intangible asset purchase commitments
Total
Disclosure of financial instruments - narrative [table]
Open hedges for anticipated transactions
Transfers out of Level 3 of fair value hierarchy, assets
Amount of change in OCI when pricing parameters for level 3 change more than 10%
Most significant foreign exchange losses
Carrying amount of long-term financial debt designated as hedge instruments
Unrealized loss was recognized in other comprehensive income and accumulated in currency translation effects in relation with this net investment hedge
Net investment hedge recognized in the income statement
Upper limit on holdings on unrelated company
Borrowings commercial paper maximum borrowing amount
Debt/equity ratio
VAR estimate confidence interval
Borrowings commercial paper maximum amount outstanding
Borrowings credit facility committed
Counterparty risk [abstract]
Percentage of entity's cash and cash equivalents held with financial institution
Vendor [axis]
Vendor [member]
Largest financial institution [member]
Second largest financial institution [member]
Third largest financial institution [member]
Pre tax profit (loss) from divestment of business
Consideration transferred, divestment-date fair value
Potential receivable from divestment
Fair value of contingent consideration received
Milestone payment already received
Future put option to sell business
Payment put option
Interest exchanged
Changes in provisions offset against gross trade receivables
Benefit payments
Number of share options exercised
Number of share options exercised or sold
Financial liabilities, at fair value
Total Novartis shares
Total treasury shares
Liabilities to banks and other institutions
Liabilities to banks and other financial institutions
Contingent consideration receivable, current
Contingent consideration receivable
Impact of divestments, other provisions
Impact of divestments
Gross carrying amount
Customers with net sales over five percent
Impairment (loss) reversal of impairment loss recognised in profit or loss
Acquired cash and cash equivalents
Prepaid post-employment benefit plans
Accrued share-based payments
Inventory
Trade receivables
Contingent consideration receivables short-term [member]
(Increase)/decrease of treasury share repurchase obligation under a share buyback trading plan
Options excluded from the calculation
US commercial paper programs [member]
JP commercial paper programs [member]
Borrowings commercial paper, number of programs
Amount of change in OCI when most significant parameters for level 3 change more than 10%
Advanced Accelerator Applications (AAA) [member]
Advanced Accelerator Applications (AAA)
Percentage of Share capital in tender offer
Cash offer per ordinary share
Cash offer per ADS
Number of ordinary share per ADS
Value of equity
Maximal amount of share buyback programm
Description of Annual Incentive
Trade payables
Trade payables
Provisions and other current liabilities
Total provisions and other current liabilities
Revenue from sale of goods, change in percent
Impact of new tax law income tax relating to deferred tax assets on US post retirement previously recognized through OCI
Deferred tax on above items
Benefits other than equity-based compensation
Key management personnel compensation, short-term employee benefits
Intangible asset impairment charges [text block]
Intangible asset impairment charges and reversals
Percentage of share capital tendered at the expiration of the tender offer
Transaction related costs paid
Transaction related costs
Amortization of fair value adjustments relating to intangible assets tax
Maximum margin percentage impact of commodity price change
Maximum holding in unrelated company
This expresses the amount of cash Novartis paid to the owners of AAA per ADS.
This expresses the amount of cash Novartis paid to the owners of AAA per ordinary share.
This expresses a maximal amount.
This expresses a limit.
This is a reclassification that can be debit or credit.
This amount can be a debit or a credit as the table discloses the fair value gain and loses on assets and liabilities.
This amount can be a debit or a credit as the table discloses the fair value gain and loses on assets and liabilities.
Selling, general and administrative expense
Increase (decrease) through other changes, equity
Other movements
Change over period [axis]
Reported value [member]
Change over period [member]
Change to prior year-end [member]
Net debt
Net debt
Net debt
Disclosure of basis of preparation of financial statements [text block]
Basis of preparation
Basis of preparation [abstract]
Selected critical accounting policies [abstract]
Summary of equity attributable to Novartis AG shareholders
Financial instruments
Legal proceedings update [abstract]
Legal proceedings update [text block]
Legal proceedings update
Impacts of adoption of new IFRS standards [abstract]
Impacts of adoption of new IFRS standards [text block]
Description of accounting policy for available-for-sale financial assets [text block]
Description of accounting policy for financial instruments [text block]
Description of accounting policy for Revenue from Contracts with Customers [text block]
Description of accounting policy for other revenue [text block]
Other revenue
Consolidated balance sheet by the adoption of IFRS 15 [table text block]
Consolidated statement of changes in equity by the adoption of IFRS 9 and IFRS 15 [table text block]
Financial instruments additional disclosures table by the adoption of IFRS 9 [table text block]
Net sales by region
Net sales of Top 20 brands
Other revenue
AveXis, Inc. [member]
AveXis, Inc.
Retrospective application and retrospective restatement [axis]
Currently stated [member]
Previously stated [member]
Increase (decrease) due to changes in accounting policy and corrections of prior period errors [member]
Increase (decrease) due to changes in accounting policy, IFRS 9 [member]
Adjustment, IFRS 9
Increase (decrease) due to changes in accounting policy, IFRS 15 [member]
Adjustment, IFRS 15
OCI reserves [member]
OCI reserves
Retail Generics [member]
Biopharmaceuticals [member]
Anti Infectives [member]
Surgical [member]
Vision Care [member]
Consumables [member]
Implantables [member]
Equipment/Other [member]
Ophthalmic OTC [member]
Contact lens care [member]
Top 20 products [member]
Rest of portfolio [member]
Royalty income
Profit sharing income
Milestone income
Other revenue, other
Other
Profit (loss) from operating activities, as a percentage from net sales
Operating income as % of net sales
Canada and Latin America [member]
Net sales, change in %, cc
Established Markets [member]
Emerging Growth Markets [member]
Rest of the world [member]
Shares acquired to be cancelled
Shares acquired for cancellation, equity impact
Increase of treasury share repurchase obligation under a share buyback trading plan
0.5% EUR 750 million 2018/2023 of Novartis [member]
1.375% EUR 750 million 2018/2030 of Novartis [member]
1.7% EUR 750 million 2018/2038 of Novartis [member]
Immunology [member]
Anti Infectives sold under Sandoz name [member]
Disclosure of detailed information about business combinations [text block]
Value adjustments related to financial assets sold and divestments
Non-current assets or disposal groups classified as held for sale
Increase (decrease) due to changes in accounting policy [member]
Increase (decrease) due to changes in accounting policy required by IFRSs [member]
Assets of disposal group held for sale
Lutathera [member]
Kymriah [member]
Percentage of share capital tendered at the subsequent offering period of the tender offer
Consideration paid for share capital tendered at the subsequent offering period of the tender offer
Total percentage of share capital tendered after the subsequent offering period of the tender offer
Transaction costs recorded in Equity [text block]
Transaction costs recorded in Equity
Transaction costs recorded in equity paid
Transactions with related parties [abstract]
Transactions with related parties [text block]
Transaction costs recorded in equity
Other comprehensive income recycled into the consolidated income statement
Increase to retained earnings arising from first application of IFRS 9 fund investments
Increase to retained earnings arising from first application of IFRS 9 equity securities
Novartis Pension Fund [member]
Borrowings credit facility uncommitted
Other net assets
Payments from changes in ownership interests in subsidiaries that do not result in loss of control
Payments from changes in ownership interests in consolidated subsidiaries
Ocular health [member]
0.500% EUR 750 million 2018/2023 of Novartis Finance S.A., Luxembourg, Luxembourg issued at 99.655% [member]
1.375% EUR 750 million 2018/2030 of Novartis Finance S.A., Luxembourg, Luxembourg issued at 99.957% [member]
1.700% EUR 750 million 2018/2038 of Novartis Finance S.A., Luxembourg, Luxembourg issued at 99.217% [member]
Advanced Accelerator Applications International SA, Geneve [member]
Advanced Accelerator Applications Switzerland SA, Geneve [member]
Novartis Gene Therapies, Inc., Bannockburn, IL [member]
Advanced Accelerator Applications S.A., Rueil-Malmaison [member]
Basic earnings per share
Diluted earnings per share
Current assets other than non-current assets or disposal groups classified as held for sale or as held for distribution to owners
Total current assets without disposal group
Current liabilities other than liabilities included in disposal groups classified as held for sale
Liabilities included in disposal groups classified as held for sale
Liabilities of disposal group held for sale
Total current liabilities without disposal group
Share of other comprehensive income of associates and joint ventures accounted for using equity method that will be reclassified to profit or loss, net of tax
Other comprehensive income that will not be reclassified to profit or loss, net of tax
Total of items that will never be recycled
Selling, general and administration
Acquisitions through business combinations, property, plant and equipment
Impact of business combinations
Disposal group held for sale [abstract]
Assets and liabilities not classified as held for sale [member]
Assets and liabilities classified as held for sale [member]
Non-current assets held for sale [member]
Disposal groups classified as held for sale [member]
Assets and liabilities classified as held for sale [axis]
Disposal group held for sale [line items]
Assets of disposal group classified as held for sale [abstract]
Liabilities of disposal group classified as held for sale [abstract]
Change in provisions and other current liabilities
Adjustments for increase (decrease) in other current liabilities
Other adjustments to reconcile profit (loss)
Change in cash settled share based payments liabilities
Other adjustments, net
Cash inflow (outflow), Non-controlling interests
Non-controlling interests
Amount recorded in equity related to hyperinflation
Additions to investment in associated companies
Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from financing activities
Currency translation effects
Increase (decrease) through obtaining or losing control of subsidiaries or other businesses, liabilities arising from financing activities
Impact of acquisitions and divestments of businesses, net
Property, plant and equipment recognised as of acquisition date
Property, plant and equipment
Financial and other assets including deferred tax assets recognised as of acquisition date
Financial and other assets including deferred tax assets
Financial liabilities recognised as of acquisition date
Non-controlling interest in acquiree recognised at acquisition date
Non-controlling interests
Other comprehensive income, net of tax, debt securities
Fair value adjustments on debt securities, net of taxes
Available-for-sale debt securities
Equity-based compensation plans
Equity-based compensation, equity impact
Increase (decrease) through share-based payment transactions, equity
Transaction costs
Gain on divestment of interests in associated companies
Gain on divestment
Fair value adjustments on debt securities [member]
Fair value adjustments on debt securities
Fair value adjustments on equity securities [member]
Fair value adjustments on equity securities
Reclassification to presentation required under IFRS 9 [member]
Restated Value Adjustments [member]
Non-current financial assets, equity securities
Non-current financial assets, fund investments
Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [abstract]
Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [table]
Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [line items]
Investments in equity instruments designated at fair value through other comprehensive income
Equity securities
Investments in equity instruments designated at fair value through other comprehensive income [axis]
Investments in equity instruments designated at fair value through other comprehensive income [member]
Listed equity securities [member]
Non-listed equity securities [member]
Disclosure of assets of disposal group classified as held for sale [table text block]
Assets of disposal group classified as held for sale
Disclosure of liabilities of disposal group classified as held for sale [table text block]
Liabilities of disposal group classified as held for sale
Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [text block]
Equity securities measured at fair value through other comprehensive income
Endocyte [member]
Endocyte
Description of accounting policy for financial assets, cash and cash equivalents [text block]
Cash and cash equivalents
Marketable securities and non-current financial assets
Disclosure of net sales and selected non-current assets, by countries and regions [table text block]
Net sales and selected non-current assets, by countries and regions
Net sales by region
Description of nature of change in accounting policy
Divestments aquisitions of interests in associated companies
Decrease through classified as held for sale, property, plant and equipment
Cost of assets related to disposal group held for sale
Decrease through classified as held for sale, intangible assets and goodwill
Cost of assets related to disposal group held for sale
Cost of assets related to disposal group held for sale
Net deferred tax balance related to disposal group held for sale
Other share sales
Other share sales
Other share sales, equity impact
Number of other share sales
Other share sales
Number of other share sales, equity impact
Other share sales, equity impact
Other comprehensive income, debt securities
Other comprehensive income, equity securities
Alcon Laboratories Belgium BVBA, Puurs [member]
Alcon AG, Fribourg [member]
Advanced Accelerator Applications USA, Inc., New York, NY [member]
CIBA Vision Corporation LLC, Duluth, GA [member]
Alcon Healthcare, S.A., Barcelona [member]
Novartis Innovative Therapies AG, Risch [member]
Sandoz Ukraine LLC, Kyiv [member]
Divestment cost to sell
Amount of settlement in principle
Number of products in portfolio to be sold
Carrying value of the divested business
Short term leases and low value leases
Remaining lease commitments
Lease liabilities to be recognized
Right of use assets to be recognized
Net gain recorded on equity securities and fund investments at fair value through the consolidated income statement
Fair value adjustments on equity securities, net of taxes
Other comprehensive income, net of tax, gains (losses) from investments in equity instruments
Deferred tax expense (income)
Deferred tax income
Current income tax expense
Current tax expense (income)
Other comprehensive income effect
Associated companies' movements in comprehensive income
Endocyte, Inc., Lafayette, IN [member]
Tear Film Innovations, Inc., Fort Worth, TX [member]
TrueVision Systems, Inc., Fort Worth, TX [member]
Novartis Baltics SIA, Riga [member]
Novartis Biosciences Peru S.A., Lima [member]
Novartis Overseas Investments AG, Basel [member]
Japat AG, Basel [member]
Alcon Management SA, Geneva [member]
Oriel Therapeutics, Inc., Durham, NC [member]
WaveLight, Inc., Sterling, VA [member]
Treasury shares with restricted use
Tax rate effect of revenues exempt from taxation
Current interest payable
Accrued interests on financial debt
Commitment for repurchase own shares
Non-current financial asstets debt securities
Additions included in disposal group prior to classification to assets held for sale
Depreciation charge prior to classification to assets held for sale
Total financial investments
Proforma net sales
Serelaxin [member]
CyPass [member]
Income statement adjustments of prior year
Adjustments of prior years charged to income statement
Income statement adjustments of current year
Current year income statement charge
Plans and program rebates [axis]
Acquisitions through business combinations, other provisions and increase (decrease) through net exchange differences, other provisions
Effects of currency translation and business acquisitions and divestments
Impairment charges related to disposal group held for sale
Impairment charges related to disposal group held for sale to the date of reclassification
Additions included in disposal group to the date of reclassification
Non-current assets divested
Current assets divested
Current liabilities divested
Other non-current assets as of acquisition date
Deferred tax liabilities recognised as of acquisition date
Deferred tax liabilities
Cash inflow outflow from net identifiable assets divested acquired
Cash inflow outflow from net identifiable assets currency translation effects liquidity and fair value of equity interests
Cash flows from losing control of subsidiaries or other businesses, classified as investing activities
Divestments of businesses, net
Fair value of other financial assets sold
Marketable securities, fair value through other comprehensive income [member]
Long-term financial investments, fair value through other comprehensive income [member]
Plans and program rebates [member]
US-specific healthcare plans and program rebates [member]
Non-US-specific healthcare plans and program rebates [member]
Non-healthcare plans and program-related rebates, returns and other deductions [member]
Depreciation charge prior to classification to assets held for sale
Deferred tax assets
Exercise prices for outstanding share options [domain]
46.7
Exercise price, 46.7 [member]
54.5
57.0
57.6
Exercise price, 57.6 [member]
66.0
Unrealized income was recognized in other comprehensive income and accumulated in currency translation effects in relation with this net investment hedge
46.4
53.7
57.1
58.3
66.1
Exercise price, 54.5 [member]
Exercise price, 57.0 [member]
Exercise price, 66.0 [member]
Exercise price, 46.4 [member]
Exercise price, 53.7 [member]
Exercise price, 57.1 [member]
Exercise price, 58.3 [member]
Exercise price, 66.1 [member]
Acquisitions and divestments of interests in associated companies, net
Transaction costs payments
Net cash flows used in investing activities from discontinued operations
Impact of new tax law income tax relating to revaluation of deferred tax assets on equity based compensation that were previously recognized through retained earnings
Prepayments and accrued lease payments
Recycling of the Novartis share of other comprehensive income from associated companies
Increase/decrease of treasury share repurchase obligation under a share buyback trading plan
Transaction costs payments
Current tax expense (income)
Deferred tax expense (income)
Total Income Tax Expense
Income tax expense from discontinued operations
Transaction costs, net of taxes
Amortization prior to classification to assets held for sale
Deferred tax assets or deferred tax liabilities related to disposal group held for sale
Accrued liability for defined benefit pension plans
Impact of business combinations
Shares acquired for cancellation, equity impact
Disposals fair value measurement assets
Total equity impact of treasury share movements
Fair value losses (including impairments and amortizations) and other adjustments recognized in the consolidated income statement
Impairment charges and fair value gains on financial assets, net
Effect of acquisitions, divestments or transfers
Other movements
Non-controlling interests
Other share purchases, equity impact
Funded status
Impairment charges and fair value gains on financial assets, net
Value adjustments related to financial assets sold and divestments
Net cash flows (used in)/from investing activities from continuing operations
Proceeds from non-current financial debts
Total net cash flows (used in)/from investing activities
Divested interest in associate
Net cash flows used in discontinued operations
Long-term financial investments [member]
Major plans percentage in group DBO pensions
Most significant countries percentage on group DBO post employment benefit plans
Settlements
Past service cost and settlements
Non-current financial assets, total financial investments
Fair value adjustments on equity securities sold, reclassified to retained earnings
Net loss from discontinued operations before gain on distribution
Difference between carrying amount of dividends payable and carrying amount of non-cash assets distributed
Gain on distribution
Deferred Tax on Pension plans previously recognized in OCI
Right-of-use assets
Dividend in kind distribution liability
Dividends payable, non-cash assets distributions
Dividend in kind
Dividends recognised as distributions to owners of paren
Sale of treasury shares
Net income from continuing operations
Net cash flows from financing activities from discontinued operations
Net cash flows used in financing activities from continuing operations
Cash flows from (used in) financing activities, discontinued operations
Cash flows from (used in) financing activities, continuing operations
Net change in cash and cash equivalents before effect of exchange rate changes
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes
Cash and cash equivalents of discontinued operations
Disclosure of discontinued operations [abstract]
Sales to other segments
Net sales to third parties
Change over period, YoY [member]
Disclosure of quantitative information about right-of-use assets [abstract]
Disclosure of quantitative information about right-of-use assets [table]
Vehicles [member]
Disclosure of quantitative information about right-of-use assets [line items]
Depreciation, right-of-use assets
Depreciation charge
Machinery & equipment and other assets
Non-current lease liabilities
Lease liabilities
Current lease liabilities
Lease liabilities
Payments of lease liabilities
Payments of lease liabilities, classified as financing activities
Presentation of leases for lessee [abstract]
Lease liabilities
Gross lease liabilities
Operating lease commitments
Presentation of leases for lesses [table]
Presentation of leases for lessee [line items]
Expense relating to short-term leases for which recognition exemption has been used
Recognition exemption for short term leases
Expense relating to leases of low-value assets for which recognition exemption has been used
Recognition exception for low value leases
New lease arrangements
Undiscounted future lease payments
Effect of discounting
Lease liability
Disclosure of quantitative information about leases for lessee [abstract]
Interest expense on lease liabilities
Cash outflow
Expense relating to variable lease payments not included in measurement of lease liabilities
Disclosure of maturity analysis of total lease liabilities [abstract]
Disclosure of maturity analysis of total lease liabilities [table]
Disclosure of maturity analysis of total lease liabilities [line items]
Net sales to third parties from continuing operations
Operating income
Restated [member]
Sale of treasury shares, number of shares
Sale of treasury shares
Detailed information about significant transaction
Takeda Pharmaceutical Company Limited [member]
Takeda Pharmaceutical Company Limited
IFM Tre, Inc. [member]
IFM Tre, Inc.
PowerVision, Inc. [member]
PowerVision, Inc.
Adjustments for prepayments and accrued lease payments
Weighted average lessee's incremental borrowing rate applied to lease liabilities recognised at date of initial application of IFRS 16
Weighted average incremental borrowing rate
Additions to right-of-use assets
Gains (losses) arising from sale and leaseback transactions
Gains or losses from sales leaseback
Other borrowings
Increase (decrease) in dividends payable through change in fair value of non-cash assets held for distribution to owners
Net assets liabilities
Net assets
Decrease of distribution liability
Potential milestone maximum payments
Number of employees associated with the product transfer
Additional borrowings
Percentage of equity interest shares received
Difference between fair value of distribution liability and net assets at the date of distribution
Distribution of dividend to dividend bearing shares to consolidated foundations
Aimovig [member]
Lease liabilities and Right of use assets Disclosure Abstract
Disclosure of leases [text block]
Reduction of issued capital
Reduction of share capital
Increase (decrease) through exercise of options, equity
Exercise of options and employee transactions, equity impact
Increase decrease through exercise of options shares
Exercise of options and employee transactions shares
Increase decrease through share based payment transactions shares
Equity based compensation shares
Repayment of lease liability
Weighted average interest rate lease liabilities
Movements of the right-of-use assets [roll forward]
Right-of-use assets at beginning of period
Right-of-use assets at end of period
Lease contract terminations, right-of-use assets
Shares delivered to divested business employees, equity impact Alcon
Taxes on treasury shares
Lease incentives
Cash inflow for leases
Net assets derecognized
Derecognition of distribution liability
Difference between net assets and distribution liability
Distribution of dividend to dividend bearing shares
Transaction costs recognized in the consolidated income statement
Difference between carrying amount of dividends payable and carrying amount of non-cash assets distributed, Net
Gain on distribution of Sandoz Group AG to Novartis AG shareholders
Net provisions for transaction costs recognized in the income statement
Cash flows attributable to divested business
Other cash flows used in investing activities, net
Other inflows (outflows) of cash, classified as investing activities
Financial and other non-current assets
Trade receivables and other current assets
Current and non-current lease liabilities
Trade payables, provisions and other liabilities
Current and non-current financial debt
Right of use assets Disclosure and Lease liabilities [abstract]
Reconciliation of lease commitment and lease liability [table text block]
Reconciliation of lease commitment and lease liability
Disclosure of quantitative information about right-of-use assets [text block]
Disclosure of quantitative information about right-of-use assets
Disclosure of Right-of-use assets roll forward [table text block]
Disclosure of Right-of-use assets roll forward
Disclosure of right-of-use assets carrying value and depreciation charge [table text block]
Disclosure of right-of-use assets carrying value and depreciation charge
Disclosure of maturity analysis of lease liability [table text block]
Disclosure of maturity analysis of lease liability
Additional disclosures related to right-of-use assets and lease liabilities [table text block]
Additional disclosures related to right-of-use assets and lease liabilities
Goodwill recognised as of acquisition date
Goodwill
Income taxes
Net financial expense
Total
Fair value of previously held equity interests
Applicable tax rate, excluding exceptional items
Current and non-current financial debt
Trade payables, provisions and other liabilities
Cash Flows Attributable to divested business before divested cash and cash equivalents
Payments out of provisions for transaction costs attributable to the divested business
Divested cash and cash equivalents
Derecognized cash and cash equivalents attributable to the spin-off of the Sandoz business
Deferred Tax on Pension plans previously recognized in OCI
Shares obtained through consolidated foundation
Customary purchase price adjustment
Repayment of intercompany balances
Tax reform impact on deferred tax on treasury shares
Dividend paid, non-cash assets distribution
Dividend in kind
Disclosure of net gain at completion of spin-off [table text block]
Net gain at completion of spin-off
Disclosure of assets and liabilities of disposal group classified as held for sale [table text block]
Assets and liabilities of disposal group classified as held for sale
Consolidated income statement, discontinued operations [table text block]
Consolidated income statement, discontinued operations
Disclosure of items included in net income from discontinued operations [table text block]
Disclosure of items included in net income from discontinued operations
Disclosure of net assets derecognized [table text block]
Disclosure of net assets derecognized
Fair value of assets and liabilities arising from divestments [table text block]
Fair value of assets and liabilities arising from divestments
Weighted average exercise price of share options outstanding in share-based payment arrangement
Weighted average exercise price of share options outstanding in share-based payment arrangement at beginning of period
Weighted average exercise price of share options outstanding in share-based payment arrangement at end of period
Weighted average exercise price of share options exercised in share-based payment arrangement
Weighted average exercise price of share options forfeited in share-based payment arrangement
Weighted average exercise price of share options exercisable in share-based payment arrangement
Weighted average remaining contractual life of outstanding share options
Exercise price of outstanding share options
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement at beginning of period
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement at end of period
Weighted average exercise price of other equity instruments granted in share-based payment arrangement
Weighted average exercise price of other equity instruments exercised or vested in share-based payment arrangement
Weighted average exercise price of other equity instruments forfeited in share-based payment arrangement
Description of accounting policy for leases
Leases and right-of-use assets
Description of accounting policy for distribution by way of divindend in kind to shareholders
Distribution by way of dividend in kind to shareholders
Aspen Global Incorporated
The Medicines Company, East Hanover, NJ [member]
The Medicines Company
Piqray [member]
Xiidra [member]
Zolgensma Group [member]
Mayzent [member]
Decrease through assets related to discontinued operations
Decrease through reclassification to right-of-use assets
Costs and accumulated depreciation/impairments on assets related to discontinued operations
Decrease through assets related to discontinued operations, intangible assets and goodwill
Costs and accumulated depreciation/impairments on assets related to discontinued operations
Accumulated amortization/impairments on assets related to discontinued operations
Net deferred tax balance at beginning of period continuing operations
Net deferred tax balance related to discontinued operations
Aspen Global Incorporated [member]
Undiscounted finance lease payments to be received
Total future payments
Unearned finance income relating to finance lease payments receivable
Unearned interest income
Minimum finace lease payments receivable at present value
Minimum lease payments from finance lease agreements, at present value
Interest payments for amounts included in lease liabilities
Interest payments for amounts included in lease liabilities classified as cash flows from operating activities
Increase through new leases, liabilities arising from financing activities
New leases
Reclassification from non-current to current, net
Interest expense on lease liabilities
Lease liabilities [member]
Contingent consideration payable
Useful life measured as period of time, intangible assets other than goodwill
Increase (decrease) due to changes in accounting policy, IFRS 16 [member]
Borrowings, USD [member]
Borrowings, EUR [member]
Finance lease liabilities
Finance lease obligations
Equity based compensation shares
Exercise of options and employee transactions shares
Exercise of options and employee transactions, equity impact
Exercise of options and employee transactions
Other non-current receivables
Other long-term receivables
Product liability, government investigations, other legal matters provisions, impact of business combinations
Impact of business combinations
Impact of adoption of IFRS 16 Leases
Financial debts cash flows from continuing operations
Previously reported finance lease obligation of divested business
Net cash flows used in acquisitions and divestments of businesses classified as investing activities from continuing operations
Derivative financial instruments, options on equity securities
Estimated financial effect of contingent liabilities, damages claimed
Additional amount of settlement in principle
Amount of resolved action
Enoxaparin [member]
Sandoz Manufacturing Inc. [member]
China Novartis Institute for BioMedical Research Co.,Ltd. [member]
Suzhou Novartis Technical Development Co., Ltd. [member]
CELLforCURE [member]
Novartis Manufacturing GmbH [member]
Novartis Hungary Healthcare Limited Liability Company [member]
Advaced Accelerator Applications (Italy) S.r.l. [member]
IDB Holland BV [member]
Advaced Accelerator Applications Iberica, S.L.U. [member]
Imaging Equipment Ltd [member]
Novartis Inflammasome Research, Inc. [member]
Novartis Technology LLC [member]
Portion of consideration paid (received) consisting of cash and cash equivalents upfront payment
Portion of consideration paid consisting of cash and cash equivalents upfront payment
Partial release of deferred tax liability recognized
Lease liabilities undiscounted
Most material lease with lease term extension
Cash outflows for short term and low value leases
Cash outflows for payments of leases interest
Impact of new tax reform applicable tax rate after implemetation of new reform changes
Impact of new tax reform applicable blended tax rate after implemetation of new reform changes
Long term receivables from finance subleases
Financial debts, derivative financial instruments and lease liabilities related to discontinued operations
Borrowings credit facility short term
Name of Property [Axis]
Name of Property [Domain]
Currency [axis]
Europe [member]
Americas [member]
Right-of-use assets [member]
Right-of-use assets
Beovu [member]
Consideration paid (received)
Net cash inflows from divestment
Net cash outflows from divestments
Cash and cash equivalents in subsidiary or businesses acquired or disposed
Increase (decrease) through transfers and other changes, other provisions
Transfers
Current liabilities [member]
Non-current liabilities [member]
Liabilities in subsidiary or businesses acquired or disposed
Current lease liabilities undiscounted
Non-current lease liabilities undiscounted
Less current lease liabilities
Less current lease liabilities undiscounted
Deferred tax expense arising from write-down or reversal of write-down of deferred tax asset
Effect of write-off of deferred tax assets
Impairment charge prior to classification to assets held for sale
Impairment charge prior to classification to assets held for sale
Tax on transaction costs recorded in equity
Tax rate, effect of write-off of deferred tax assets
Effect of derecognition and reversals of derecognition of deferred tax assets
Proceeds from current and non-current borrowings
Transaction costs payment
Uncalled capital commitments for investments in funds
Litigation Case [member]
Tennessee class action [member]
Massachusetts case [member]
Document Annual Report
Entity Shell Company
Entity Emerging Growth Company
Entity Interactive Data Current
Cash inflow from borrowings
Transaction cost payments
Gross deferred tax assets
Gross deferred tax liabilities
Gross deferred tax liabilities
Amount borrowed under the credit facility
Contingent consideration liabilities
Litigation case [axis]
Document Transition Report
Document Shell Company Report
Accumulated depreciation, amortisation and impairment [member]
Accumulated depreciation, amortisation and impairment
Impact of new tax law income tax relating to deferred tax assets on Swiss post retirement previously recognized through OCI
Impact of new tax law income tax relating to deferred tax assets on Swiss post retirement previously recognized through OCI
Taxes on treasury share transactions
Costs of assets related to discontinued operations
Decrease through reclassification to right-of-use assets
Recognition exemption for short term leases
Recognition exception for low value leases
Effect of discounting
Right-of-use assets depreciation charge
Lease contract terminations, right-of-use assets
Less current lease liabilities undiscounted
Inventory provisions
Current trade receivables from closely monitored countries past due more than one year, provisions recorded
Fair value of previously held equity interests
Proceeds from non-current financial debts
Amortization of bonds discount
Contributions of employees
Currency translation effects
Effect of acquisitions, divestments or transfers
Currency translation effects
Contingent consideration liabilities
Net assets derecognized
Percentage of entitys trade receivable
Repayment of lease liability
Cash inflow for sale and leaseback
Sale and lease back [member]
Sale and leaseback
Current refunds provision
Provisions for deductions from revenue
Provisions for deductions from revenue, at beginning of period
Provisions for deductions from revenue, at end of period
Derivative financial instruments, commodity purchase contract
Lease liability
Effect of income not subject to tax on divestment gain
Cash inflow for sale and leaseback
Suzhou Novartis Technical Development Co., Ltd., Changshu [member]
CELLforCURE, Les Ulis [member]
Advanced Accelerator Applications (Italy) S.r.l., Colleretto Giacosa [member]
Novartis Netherlands B.V., Amsterdam [member]
Novartis Pharma B.V., Amsterdam [member]
IDB Holland BV, Baarle-Nassau [member]
Novartis Saudi Ltd., Riyadh [member]
Advanced Accelerator Applications Iberica, S.L.U., Barcelona [member]
Novartis UK Limited, London [member]
Novartis Pharmaceuticals UK Limited, London [member]
Novartis Grimsby Limited, London [member]
Imaging Equipment Ltd, London [member]
Ziarco Group Limited, London [member]
Novartis Finance Corporation, East Hanover, NJ [member]
Novartis Capital Corporation, East Hanover, NJ [member]
Novartis US Foundation, East Hanover, NJ [member]
Advanced Accelerator Applications USA, Inc., Millburn, NJ [member]
Novartis Inflammasome Research, Inc., East Hanover, NJ [member]
Novartis Technology LLC, Inc., East Hanover, NJ [member]
Encore Vision, Inc., East Hanover, NJ [member]
Endocyte, Inc., East Hanover, NJ [member]
Novartis Vaccines and Diagnostics, Inc., East Hanover, NJ [member]
Spinifex Pharmaceuticals, Inc., East Hanover, NJ [member]
Novartis Manufacturing GmbH, Marburg [member]
Payments of lease liabilities, net
Interest payments for amounts included in lease liabilities classified as cash flows from operating activities
Amortization of bonds discount
Transfers out of Level 3 of fair value hierarchy, assets
Amount of change in OCI when POS for level 3 change more than 10%
Repayments of the current portion of non-current financial debts
Effect of US tax reform legislation
Acquired cash and cash equivalents
Acquired cash and cash equivalents
Disclosure of impact on adoption of IFRS 16
Disclosure of impact on adoption of IFRS 16 [table text block]
Consolidated income statement, additional information [table text block]
Consolidated income statement, additional information
Balance sheet, additional information [table text block]
Balance sheet, additional information
Cash flows used in investing activities [table text block]
Cash flows used in investing activities
CH Corporate tax rate, impact on the revaluation of deferred assets and liabilities and current income tax liabilities [text block]
CH Corporate tax rate, impact on the revaluation of deferred assets and liabilities and current income tax liabilities
Ultibro Group [member]
Adakveo [member]
Novartis Capital Corporation, New York, United States, 1.75%, 2025 [member]
Novartis Capital Corporation, New York, United States, 2.00%, 2027 [member]
Novartis Capital Corporation, New York, United States, 2.20%, 2030 [member]
Novartis Capital Corporation, New York, United States, 2.75%, 2050 [member]
Current tax assets, current
Income tax receivables
Provisions and other non-current liabilities
Total provisions and other non-current liabilities
ZPL389 [member]
Repayment of intercompany balances
Right of use assets as of acquisition date
Right-of-use assets
Current and non current lease liabilities as of acquisition date
Current and non-current lease liabilities
Payments attributable to the spin-off of the Sandoz business
Cash flows attributable to the spin-off of the Alcon business
Proceeds from sale of property, plant and equipment
Proceeds from exercised options and other treasury share transactions, net
Impairment loss recognised in profit or loss, intangible assets and goodwill
Intangible assets impairment charges
Transaction costs recognized in the consolidated income statement
Prepaid sales price for a business divestment
Current refunds provision, Discontinued operations
Provisions for deductions from revenue, discontinued operations
Provisions for deductions from revenue, discontinued operations, at beginning of period
Provisions for deductions from revenue, discontinued operations, at end of period
Provision for doubtful receivable
Provision for doubtful receivable at beginning of period
Provision for doubtful receivable at end of period
Defined benefit obligation, discontinued operations, at present value
Benefit obligation, discontinued operations at beginning of period
Benefit obligation, discontinued operations at end of period
Lease liabilities, impact of adoption of IFRS 16
Contributions to plan by plan participants, net defined benefit liability (asset), benefit obligation
Contributions of employees
Operating lease commitments, discontinued operations
Gross lease liabilities, Discontinued operations
Increase/Decrease through classified as held for sale, intangible assets and goodwill
Cost of assets related to disposal group held for sale
Treasury shares movement of period
Treasury shares movement of period
Decrease in finance leases receivable due to unearned finance income relating to finance lease payments receivable
Other financial liabilities, category [member]
Other current assets [member]
Fair value adjustments on financial instruments [member]
dup_1_Fair value adjustments on marketable securities
Value Adjustment Increase Decrease Through Changes In Ownership Interests In Subsidiaries That Do Not Result In Loss Of Control
Impact of change in ownership of consolidated entities
Repurchase of options
Repurchase of options
Tabrecta [member]
Kesimpta [member]
1.750% USD 1 000 million 2020/2025 Novartis Capital Corporation, New York, United States, issued at 99.852% [member]
2.000% USD 1 250 million 2020/2027 Novartis Capital Corporation, New York, United States, issued at 99.909% [member]
2.200% USD 1 500 million 2020/2030 Novartis Capital Corporation, New York, United States, issued at 99.869% [member]
2.750% USD 1 250 million 2020/2050 Novartis Capital Corporation, New York, United States, issued at 97.712% [member]
0.000% 1 EUR 1 850 million 2020/2028 Novartis Finance S.A., Luxembourg, Luxembourg, issued at 99.354% [member]
Accumulated amortization/impairments on assets held for sale intangible assets and goodwill
Accumulated amortization/impairments on assets reclassified out of assets of disposal group held for sale
Increase decrease through classified as held for sale property plant and equipment
Cost of assets reclassified out of assets of disposal group held for sale
Accumulated amortization/impairments on assets held for sale property plant and equipment
Accumulated depreciation on assets reclassified out of assets of disposal group held for sale
Fair value adjustments on equity securities, net of taxes
Number of options repurchased
Property, plant and equipment depreciation charge
Property, plant and equipment impairment charges
Intangible assets amortization charge
Number of shares issued
Number of shares issued at beginning of period
Number of shares issued at end of period
Number of treasury shares
Number of treasury shares at beginning of period
Number of treasury shares at end of period
Not subject to expiry [member]
Commitment for repurchase of own shares [member]
Description of accounting policy for healthcare contributions [text block]
Healthcare contributions
Research and development commitments for transactions entered into current year, closed after current year end
Contingent consideration payables, net
CHINA
China
Tax loss carry forwards
dup_1_Tax loss carryforwards expired
Weighted average share price for share options in share-based payment arrangement exercised during period at date of exercise
Additions to investment in associated companies
Deferred tax liabilities
Borrowings interest rate step up
dup_1_Straight bonds
Assets other than cash or cash equivalents in subsidiary or businesses acquired or disposed
Non-current assets divested
Non-current assets [member]
Estimated acquisition fair value of total consideration
Estimated fair value purchase price
ICFR Auditor Attestation Flag
Novartis contributions
Spark Therapeutics, Inc. [member]
Novartis Integrated Services Limited, Ringaskiddy, County Cork [member]
Novartis Gene Therapies EU Limited, Dublin [member]
Aspen Japan K.K., Tokyo [member]
Catalana de Dispensacion sau (Cadisa), Esplugues de Llobregat [member]
Advanced Accelerator Applications (UK & Ireland), London [member]
Neutec Pharma Limited, London [member]
Coalesce Product Development Limited, Cambridge, Cambs [member]
Novartis Optogenetics Research, Inc., East Hanover, NJ [member]
Amblyotech Inc., East Hanover, NJ [member]
Novartis Vietnam Company Limited, Ho Chi Minh City [member]
Novartis Deutschland GmbH, Nuremberg [member]
Commitment for repurchase own shares
Disclosure of operating segments, balance sheet and income statement [table text block]
Segmentation - Consolidated balance sheets and income statement
Number of brands in portfolio to acquire
Number of markets for the acquired brands
Total anti-infectives net sales [member]
GlaxoSmithKline plc (GSK) [member]
Current deferred income other than current contract liabilities
Leqvio [member]
Equity-Based Participation Annual Incentive RSU [member]
dup_1_Annual incentive
Equity Based Participation Annual Incentive Restricted Shares [member]
dup_2_Annual incentive
Equity Based Participation Annual Incentive Shares [member]
dup_3_Annual incentive
Equity Based Participation Share savings plans RSU [member]
dup_4_Annual incentive
Equity Based Participation Share savings plans Shares [member]
dup_5_Annual incentive
Equity Based Participation Novartis Equity Plan Select North America RSU [member]
dup_6_Annual incentive
Based Participation Novartis Equity Plan Select outside North America RSU [member]
dup_7_Annual incentive
Equity Based Participation Novartis Equity Plan Select outside North America Restricted Shares [member]
dup_8_Annual incentive
Equity Based Participation Long Term Performance PSU Plan [member]
dup_9_Annual incentive
Equity Based Participation Long Term Relative Performance Plan PSU [member]
Equity Based Participation Other share awards RSU [member]
dup_11_Annual incentive
Equity Based Participation Other share awards Restricted Shares [member]
dup_12_Annual incentive
Equity Based Participation Other share awards Shares [member]
dup_13_Annual incentive
Cash transferred
Purchase of investments other than investments accounted for using equity method
Purchases of financial assets
Proceeds from sales of investments other than investments accounted for using equity method
Proceeds from sale of financial assets
Investments in time deposits and marketable securities
Purchase of financial instruments, classified as investing activities
Proceeds from time deposits and from sale of marketable securities
Proceeds from sales or maturity of financial instruments, classified as investing activities
Property, plant and equipment impairment charges and reversals [table text block]
Potential impact on the consolidated income statement due to increase (decrease) in currency exchange rates [table text block]
Potential impact on the consolidated income statement due to increase (decrease) in currency exchange rates
Potential impact on the consolidated income statement due to increase (decrease) in equity prices [table text block]
Potential impact on the consolidated income statement due to increase (decrease) in equity prices
Potential impact on the consolidated statements of comprehensive income due to increase (decrease) in equity prices [table text block]
Potential impact on the consolidated statements of comprehensive income due to increase (decrease) in equity prices
Gyroscope Therapeutics Holdings plc. [member]
Glaxosmithkline Consumer Healthcare Holdings Limited, Brentford, Middlesex
GlaxoSmithKline plc (GSK)
Gyroscope Therapeutics Holdings plc.
Auditor Firm ID
Auditor Name
Auditor Location
Business Contact [Member]
Address Type [Domain]
Entity Addresses, Address Type [Axis]
Entity File Number
Entity Incorporation, State or Country Code
Entity Address, Address Line One
Entity Address, City or Town
Entity Address, Postal Zip Code
Entity Address, Country
Document Registration Statement
Document Accounting Standard
Contact Personnel Name
Local Phone Number
Contact Personnel Fax Number
Net investment hedge
Commitments for leases not yet commenced
GREECE
Greece
Transfers into Level 3 of fair value hierarchy, assets
Contract manufacturing [member]
Potential impact on the consolidated equity due to increase (decrease) in currency exchange rates [table text block]
Potential impact on the consolidated equity due to increase (decrease) in currency exchange rates
Potential impact on the consolidated equity due to increase (decrease) in equity prices [table text block]
Potential impact on the consolidated equity due to increase (decrease) in equity prices
Increase/(Decrease) through new, modified, terminated leases, arising from financing activities
New, modified and terminated leases, net
Exercise price, 65.9 [member]
65.9
Scenario [Domain]
Scenario [Axis]
Hypothetical 5% increase [member]
Hypothetical 5% decrease [member]
Hypothetical 15% decrease [member]
Hypothetical 15% increase [member]
Currency exchange rate sensitivity impact against USD in the income statement
Currency exchange rate sensitivity impact against USD in the equity
In the sensitivity disclosure, no amounts have been recorded in the accounts, as it is a hypothetical scenario if interest rates would increase/decrease.
Equity price sensitivity impact of the risk factors in the income statement
In the sensitivity disclosure, no amounts have been recorded in the accounts, as it is a hypothetical scenario if interest rates would increase/decrease.
Equity price sensitivity impact of the risk factors in the equity
In the sensitivity disclosure, no amounts have been recorded in the accounts, as it is a hypothetical scenario if interest rates would increase/decrease.
Hypothetical increase decrease percentage in currency rate sensitivity
Hypothetical increase decrease percentage in equity price sensitivity
In the sensitivity disclosure, no amounts have been recorded in the accounts, as it is a hypothetical scenario if interest rates would increase/decrease.
Change in other current and non-current assets
Adjustments for decrease (increase) in other assets
Reimbursements from plan to employer net defined benefit liability (asset)
Contingent consideration recognised as of acquisition date
Fair value of fund investments and equity securities
Percentage of government backed debt securities
Number of investments in equity instruments designated at fair value through other comprehensive income
Dividends recognised for investments in equity instruments designated at fair value through other comprehensive income, held at end of reporting period
Cellerys AG, Schlieren [member]
Arctos Medical AG, Bern [member]
Kedalion Therapeutics, Inc., Menlo Park, CA [member]
Cadent Therapeutics, Cambridge, MA [member]
Number of bearer shares
Executive Committee members who stepped down
Related parties, number of executive committee members who stepped down
Related parties, number of executive committee members
Fair value adjustments on equity securities sold [member]
Fair value adjustments on equity securities sold
Increase/decrease due to revision of prior year amounts [member]
Country Region
City Area Code
Other Promoted Brands [member]
Pluvicto [member]
Scemblix [member]
Mature Ophtha [member]
Other Respiratory [member]
Non-current contingent consideration liabilities [member]
Current financial liabilities at fair value [member]
Non-current financial liabilities at fair value [member]
Disclosure of impairment loss and reversal of impairment loss [text block]
Other Hematology [member]
Other Solid Tumor [member]
Deferred sale price and other adjustments
dup_1_Divested business
Estimated financial effect of contingent liabilities, compensation for moral damages
Other net cash inflows from divestments
dup_2_Divested business
Cash outflows due to derecognized cash and cash equivalents
dup_3_Divested business
Acquisition of assets (other than through business combinations) by assuming directly related liabilities
Number of commercial organizational units
Schedule of share value adjustments currency translation effects [table text block]
Schedule of share value adjustments currency translation effects
Franchise [axis]
Non-current and current liabilities divested
Net identifiable assets of divested business
Other adjustments for non-cash items
Other
Additions to restructuring provisions
Disclosure of net sales by core therapeutic area and established brands [table text block]
Carrying value and remaining amortization period of the most significant assets within currently marketed products [text block]
Carrying value and remaining amortization period of the most significant assets within currently marketed products
Potential impact on the consolidated income statement due to increase (decrease) in interest rates [table text block]
Potential impact on the consolidated income statement due to increase (decrease) in interest rates
Currency translation reserve for net investment hedge, net of taxes
Lease term end date
Hypothetical 100-basis point increase [member]
Hypothetical 100-basis point decrease [member]
Interest rate sensitivity impact in the income statement
Hypothetical increase decrease basis point in interest rate sensitivity
Intangible assets material to entity
Carrying value
Remaining amortisation period of intangible assets material to entity
Remaining amortisation period
Provisions for doubtful trade receivables charged to the consolidated income statement
Effective income tax rate reconciliation other adjustments
Other tax effects for reconciliation between accounting profit and tax expense (income)
Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from experience adjustments
Experience-related remeasurement losses/(gains)
Decrease (increase) in net defined benefit liability (asset) resulting from return on plan assets excluding interest income or expense
Return on plan assets excluding interest income
Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on changes in effect of limiting net defined benefit asset to asset ceiling excluding interest income or expense
Change in limitation on recognition of fund surplus
Increase (decrease) in net defined benefit liability (asset) resulting from administration costs not reflected in return on plan assets
Administrative expenses
Employee benefits expense
Personnel costs
Equity-Based Participation Employee share purchase plan [member]
Share purchase plans
Novartis Gene Therapies France S.A.S., Rueil-Malmaison [member]
Advanced Accelerator Applications Molecular Imaging France, Saint Genis Pouilly [member]
Interest income on limitation of fund surplus
Interest income on limitation of fund surplus
Interest income on limitation of fund surplus
Increase/Decrease through changes in foreign exchange rates fund surplus
Currency translation effects
Currency translation effects
Value adjustments related to divestments [member]
Value adjustments related to divestments
Gyroscope Therapeutics Limited, London [member]
Payment of interest bearing accounts to beneficiaries
Cash outflows from interest bearing accounts of employees payable on demand
Interest cost
Administrative expenses
Interest income
The increase in a defined benefit pension plan's projected benefit obligation or a defined benefit postretirement plan's accumulated postretirement benefit obligation due to the passage of time.
Administration costs not reflected in return on plan assets, defined benefit plans
Administrative expenses
Interest income, defined benefit plans
Interest income
American Depositary Shares each representing 1 share [member]
American Depositary Shares each representing 1 share
Ordinary shares, nominal value CHF 0.50 per share [member]
Ordinary shares, nominal value CHF 0.50 per share*
Title of 12(b) Security
Security Exchange Name
In the sensitivity disclosure, no amounts have been recorded in the accounts, as it is a hypothetical scenario if interest rates would increase/decrease.
Non-current financial assets, total financial investments
Description of reasons for transfers out of Level 3 of fair value hierarchy, assets
Disclosure of material accounting policy information [text block]
Disclosure of significant accounting policies [abstract]
Change over prior period [member]
Other Finance income received, classified as operating activities
Other financial receipts
Piqray/Vijoice [member]
Other comprehensive income from continuing operations
Other comprehensive income from discontinued operations
Disclosure of revenues and geographic information [abstract]
Disclosure of revenue [text block]
Revenues and geographic information
Chinook Therapeutics [member]
Chinook Therapeutics
Sandoz Group AG [member]
Sandoz Group AG
Number of organizational units
Revenue from sale of goods, change in percent, cc
Oncology [member]
Other comprehensive income from discontinued operations, net of taxes
Decrease through assets related to discontinued operations right of use assets
Costs of assets related to discontinued operations
Net income from discontinued operations before gain on distribution
Classes of IPR&D programs [axis]
IPR&D programs [member]
PPY988 [member]
dup_2_Intangible assets
dup_2_Intangible assets [member]
VDT482 [member]
dup_3_Intangible assets
dup_3_Intangible assets [member]
NIZ985 [member]
dup_4_Intangible assets
dup_4_Intangible assets [member]
UNR844 [member]
dup_5_Intangible assets
dup_5_Intangible assets [member]
GTX312 [member]
dup_6_Intangible assets
dup_6_Intangible assets [member]
DTx Pharma Inc. [member]
DTx Pharma Inc.
Later than one year
Potential milestone maximum received
Document Financial Statement Error Correction [Flag]
Shares delivered to divested business employees, equity impact Sandoz
Effect of income not subject to tax
Minimum taxation rate
Shares delivered to divested business employees Sandoz
Novartis Holding GmbH, Vienna [member]
Novartis Pharmaceutical Manufacturing GmbH, Langkampfen [member]
Novartis Caribe, S.A., Santo Domingo [member]
Novartis Pharma Vertriebs GmbH, Nuremberg [member]
Novartis Integrated Services Limited, Dublin [member]
Aduro Netherlands Cooperatief U.A., Amsterdam [member]
Aduro Biotech Holdings Europe B.V., Amsterdam [member]
Novartis farmacevtska proizvodnja d.o.o., Ljubljana [member]
Advanced Accelerator Applications Iberica, S.L.U., La Almunia de Dona Godina [member]
DTX Pharma, Inc., San Diego, CA [member]
dup_1_The Medicines Company
Chinook Therapeutics, Inc., Seattle, WA [member]
dup_2_The Medicines Company
Chinook Therapeutics U.S., Inc., Seattle, WA [member]
dup_3_The Medicines Company
Novartis Manufacturing LLC, East Hanover, NJ [member]
Disclosure of net sales from continuing operations [table text block]
Net sales from continuing operations
Disclosure net income from discontinued operations [table text block]
Net income from discontinued operations
Disclosure net assets derecognized [table text block]
Net assets derecognized
Disclosure items included in net income from discontinued operations [table text block]
Items included in net income from discontinued operations
Disclosure additions to property, plant and equipment, right-of-use assets and goodwill and intangible assets for discontinued operations [table text block]
Additions to property, plant and equipment, right-of-use assets and goodwill and intangible assets for discontinued operations
Disclosure net cash flows used in investing activities from discontinued operations [table text block]
Net cash flows used in investing activities from discontinued operations
Cash flows from changes in working capital and other operating items included in operating cash flow [table text block]
Cash flows from changes in working capital and other operating items included in operating cash flow
Number of sale and lease-back transactions completed
Later than one year and not later than two years
MBG453 [member]
dup_7_Intangible assets
dup_7_Intangible assets [member]
Financial debts and derivative instruments
Financial debts, derivative financial instruments and lease liabilities at beginning of period
Decrease through liabilities related to discontinued operations
Commitments related to acquisitions of businesses and interests in intellectual property
Current debt and equity securities [member]
Financial instruments carrying value level 3 discontinued operations
Net investment hedge recognized in the consolidated income statement
Information about lessee's exposure arising from extension options and termination options
Other borrowings [axis]
Other borrowings [member]
Bridge loan [member]
Term loan [member]
Fair value of plan assets discontinued operations at end of period
Fair value of plan assets discontinued operations
Fair value of plan assets discontinued operations at beginning of period
Limitation on recognition of fund surplus discontinued operations
Limitation on recognition of fund surplus discontinued operations at beginning of period
Limitation on recognition of fund surplus discontinued operations at end of period
Net liability (asset) discontinued operations
Net liability in the balance sheet discontinued operations at end of period
Net liability discontinued operations at end of period
Net liability discontinued operations at beginning of period
Reduction par value per share
Amount of share buyback programm related to irrevocable, non-discretionary arangement
Local bilateral facilities [member]
Income taxes paid refund classified as operating activities discontinued operations
Income taxes paid refund classified as operating activities total company
Benefit obligation, discontinued operations at beginning of period
Fair value of plan assets discontinued operations at beginning of period
Limitation on recognition of fund surplus discontinued operations at beginning of period
Costs and accumulated depreciation/impairments on assets related to discontinued operations
Administrative expenses
Return on plan assets excluding interest income
Document Financial Statement Restatement Recovery Analysis [Flag]
Tax losses carried forward that expired [table text block]
Tax losses carried forward that expired
Payments, deferred consideration and other adjustments, net
Disclosure of changes in accounting policies, accounting estimates and errors [text block]
Disclosure of detailed information about borrowings [text block]
Disclosure of detailed information about borrowings
Disclosure of other operating income (expense) [text block]
Disclosure of other income and expense [abstract]
Disclosure of other income and expense
Disclosure of other income and expense [table text block]
Other expense [abstract]
Expense of restructuring activities
Expense of restructuring activities
Total other expense
Total other income
Restructuring related income
Business divestment related income
Business divestment related expenses
Business divestment related expenses
Litigation and settlement income
Litigation and settlement costs
Litigation and settlement costs
Miscellaneous other operating income
Miscellaneous other operating expense
Miscellaneous other operating expense
Intangible assets and goodwill [member]
Intangible assets
Intangible assets [member]
Fabhalta [member]
Equity [member]
Disposals and retirements, right-of-use assets
Impact of divestments
Acquisitions through business combinations, right-of-use assets
Impact of business combinations
Increase (decrease) through net exchange differences, right-of-use assets
Stock repurchase program, authorized amount
Shares repurchased on the SIX Swiss Exchange second trading line under the share buyback authority approved
Kate Therapeutics, Inc.
Kate Therapeutics, Inc. [member]
Cash flow hedge, net of taxes
Effect of pillar two taxes
Hedging reserves [member]
Hedging reserves
Value adjustments regognized through equity
Later than four years [member]
dup_1_Sale and leaseback
Interest for discounting lease liabilities
MorphoSys AG
Other bonds
Average interest rate on other bonds
Total bonds
dup_1_Liabilities to banks and other financial institutions
1.600% CHF 650 million 2024/2027 Novartis AG, Basel, Switzerland, issued at 100.138% [member]
1.650% CHF 435 million 2024/2031 Novartis AG, Basel, Switzerland, issued at 100.148% [member]
1.750% CHF 645 million 2024/2034 Novartis AG, Basel, Switzerland, issued at 100.229% [member]
1.850% CHF 280 million 2024/2040 Novartis AG, Basel, Switzerland, issued at 100.268% [member]
1.850% CHF 190 million 2024/2049 Novartis AG, Basel, Switzerland, issued at 100.149% [member]
3.800% USD 1 000 million 2024/2029 Novartis Capital Corporation, New York, United States, issued at 99.757% [member]
4.000% USD 850 million 2024/2031 Novartis Capital Corporation, New York, United States, issued at 99.565% [member]
4.200% USD 1 100 million 2024/2034 Novartis Capital Corporation, New York, United States, issued at 99.282% [member]
4.700% USD 750 million 2024/2054 Novartis Capital Corporation, New York, United States, issued at 99.936% [member]
Deferred income
Repayments of current borrowings
Repayments of other current financial debts
Payments from changes in ownership interests in consolidated subsidiaries
Investments in equity instruments designated at fair value through other comprehensive income [domain]
Classes of property, plant and equipment [domain]
Environmental provision
Mariana Oncology, Inc. [member]
Mariana Oncology, Inc.
MorphoSys AG [member]
Proportion of ownership interests held by non-controlling interests
Percentage of share capital purchased by the company outside the tender offer
Reduction of non-controlling interests
Financial investments and other receivable
Financial debt to third parties
Other net liabilities
Purchase of non-controlling interests
Percentage of share capital owned
Payment to the former remaining minority shareholders
Realized gain on commodities
Reclassification adjustments on cash flow hedges, before tax
Other comprehensive income net of tax gains losses remeasurement of cash flow hedge reclassified to profit and loss
Less current lease liabilities interests for discounting
Repayments of other current financial debts
Other bonds [member]
Useful life measured as period of time, property, plant and equipment
Borrowings commercial paper amount outstanding
Weighted average interest rate
Replacement of credit facility with a syndicate of banks [member]
Interest expense on hedge item recycled through the income statement
Minimum top-up tax rate on the profits of foreign subsidiaries
Schedule of Inventory, Current [table text block]
Schedule of Earnings Per Share, Basic and Diluted [table text block]
Schedule of Deferred Tax Assets and Liabilities [table text block]
Schedule of Deferred Tax Assets and Liabilities
Marketing related intangible assets [member]
Inventories [member]
Carrying reported amount fair value disclosure [member]
Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage
Schedule of assumptions used [table text block]
Schedule of health care cost trend rates [table text block]
The fair value of plan asset allocation of funded defined benefit pension plans [text block]
Schedule of expected benefit payments [table text block]
Accrual for taxes other than income taxes, current
Defined benefit plan, recognized net gain (loss) due to curtailments
Defined Benefit Plan, Settlements, Plan Assets
Settlements
Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year
Rate to which the cost trend rate is assumed to decline
Defined Benefit Plan, Health Care Cost Trend Rate Assumed to Decline
Defined Benefit Plan, Year that Rate Reaches Ultimate Trend Rate
Real estate [member]
Corporate [member]
Schedule of unvested restricted stock units roll forward [table text block]
Defined benefit plan, interest cost
Inventory
Effect of income not subject to tax
Novartis Pharmaceutical Technology Zhejiang Co., Ltd., Haiyan [member]
MorphoSys GmbH, Planegg [member]
Calypso Biotech B.V., Amsterdam [member]
Novartis Kapital AG, Basel [member]
Novartis BidCo AG, Basel [member]
Pharmanalytica SA, Locarno [member]
Renor AG, Basel [member]
Calypso Biotech SA, Plan-les-Ouates [member]
Kate Therapeutics Inc., San Diego, CA [member]
Constellation Pharmaceuticals, Inc., Boston, MA [member]
Mariana Oncology Inc., Watertown, MA [member]
MorphoSys US Inc., Boston, MA [member]
Novartis Uruguay S.A., Inc., Montevideo [member]
dup_4_The Medicines Company
Other net assets liabilities
Long-term loans, advances and security deposits
dup_1_Contingent consideration receivables
Net identifiable assets acquired
Contractual commitments for acquisition of intangible assets
Commitments under long-term research and development agreements
Capitalized development costs
dup_1_Capitalized development costs
Tax rate effect of impairment of goodwill
Effect of non-deductible impairment of goodwill
Effect related to Swiss Patent Box regime
Disclosure of instruments with potential future dilutive effect not included in calculation of diluted earnings per share [text block]
Discount rate for voluntary employee share purchase plan
Contributions of employees
Less current lease liabilities interests for discounting
Interest expense on hedge item recycled through the income statement
Interest for discounting lease liabilities
Less current lease liabilities interests for discounting
Interest expense on hedge item recycled through the income statement
Ordinary shares, nominal value CHF 0.49 per share [member]
Ordinary shares, nominal value CHF 0.49 per share*
Payments from plan defined benefit asset
Payments from plan defined benefit asset
Benefit payments
Equity-based compensation plans and employee transactions, shares
Equity-based compensation plans and employee transactions, equity impact
Increase/decrease through changes in ownership interests in subsidiaries without loss of control
Increase/decrease through other changes in equity
Increase/decrease through other changes in equity, shares
Total other revenues
Total other comprehensive income
Other comprehensive income [abstract]
Acquisitions applying the optional concentration test
Identifiable net assets acquired through acquisitions applying the optional concentration test [table text block]
Identifiable net assets acquired through acquisitions applying the optional concentration test
Identifiable net assets acquired through acquisitions applying the optional concentration test
Identifiable net assets acquired through acquisitions applying the optional concentration test
Property, plant and equipment recognised as of acquisition date [member]
Property, plant and equipment recognised as of acquisition date
Right of use assets as of acquisition date [member]
Right of use assets as of acquisition date
Acquired research and development intangible assets recognised as of acquisition date [member]
Acquired research and development intangible assets recognised as of acquisition date
Deferred tax assets [member]
Deferred tax assets
Non-current financial and other assets [member]
Non-current financial and other assets
Trade receivables and other current assets recognised as of acquisition date [member]
Trade receivables and other current assets recognised as of acquisition date
Cash and cash equivalents recognised as of acquisition date [member]
Cash and cash equivalents recognised as of acquisition date
Current and non-current lease liabilities [member]
Current and non-current lease liabilities
Trade payables and other liabilities [member]
Trade payables and other liabilities
Regulus Therapeutics Inc. [member]
Regulus Therapeutics Inc.
Anthos Therapeutics Inc. [member]
Anthos Therapeutics Inc.
Cash offer per outstanding share for acquisitions applying the optional concentration test
Contingent value right per share for acquisitions applying the optional concentration test
Portion of consideration paid consisting of cash and cash equivalents for acquisitions applying the optional concentration test
Portion of consideration paid consisting of cash and cash equivalents for acquisitions applying the optional concentration test
Number of contingent value per share issued for acquisitions applying the optional concentration test
Liability related to employee share plans for acquisitions applying the optional concentration test
Contingent value right amount for acquisitions applying the optional concentration test
Intangible assets other than goodwill for acquisitions applying the optional concentration test
Other net assets for acquisitions applying the optional concentration test
Potential milestone maximum payment for acquisitions applying the optional concentration test
Receipts from royalties, fees, commissions and other revenue
Applicable Swiss blended tax rate
New applicable Swiss blended tax rate
Applicable Swiss cantonal tax rate
New applicable Swiss cantonal tax rate
Applicable US Federal tax rate
Disclosure of additions excluding the impact of business acquisitions [table text block]
dup_1_Disclosure of other income and expense
Other finance costs paid classified as operating activities
Other financial payments
Cash and cash equivalents acquired through acquisitions applying the optional concentration test
dup_1_Acquisitions applying optional concentration test
Other expense related to legal matters
Percentage of share capital tendered after the expiration of the tender offer
Effect of the settlement of share based compensation plans
Percentage of share capital purchased by the company during the tender offer
Other equity shareholdings [member]
Other equity shareholdings
Trade and other payables recognised as of acquisition date
Trade payables and other liabilities
Vanrafia [member]
Rhapsido [member]
Tourmaline Bio, Inc. [member]
Tourmaline Bio, Inc.
Private clinical-stage biotech company [member]
Private clinical-stage biotech company
SOFR + 0.52% USD 800 million 2025/2028 Novartis Capital Corporation, New York, United States, issued at 100.000% [member]
3.900% USD 700 million 2025/2028 Novartis Capital Corporation, New York, United States, issued at 99.978% [member]
4.100% USD 1 750 million 2025/2030 Novartis Capital Corporation, New York, United States, issued at 99.700% [member]
4.300% USD 925 million 2025/2032 Novartis Capital Corporation, New York, United States, issued at 99.409% [member]
4.600% USD 925 million 2025/2035 Novartis Capital Corporation, New York, United States, issued at 99.564% [member]
5.200% USD 350 million 2025/2045 Novartis Capital Corporation, New York, United States, issued at 99.889% [member]
5.300% USD 550 million 2025/2055 Novartis Capital Corporation, New York, United States, issued at 99.464% [member]
Non-controlling interests for acquisitions applying the optional concentration test
Portion of consideration paid received consisting of cash and cash equivalents upfront payment for acquisitions applying the optional concentration test
Floating rate bonds [member]
Borrowings, interest rate basis
Fixed interest rate [member]
Floating interest rate [member]
Types of interest rates [domain]
Types of interest rates [axis]
Disclosure of marketable securities deposits derivative instruments and cash and cash equivalents [text block]
Description of accounting policy for financial assets, marketable securities and non-current financial assets [text block]
Derivative financial instruments
Marketable securities, time deposits, and derivative financial instruments [table text block]
Tax rate effect related to pillar two
Disclosure of components of non-current financial debts [line items]
Expense from equity-settled share-based payment transactions
Expense from cash-settled share-based payment transactions
Voluntary payroll deductions on share based payment transactions with employees
Debt and equity securities [member]
Contractual interest on non-current financial debt, including current portion
Societe Civile Immobiliere de la Schiffmuehle, Huningue [member]
Novartis Lateinamerika AG, Basel [member]
Anthos Therapeutics, Inc., East Hanover, NJ [member]
Regulus Therapeutics Inc., San Diego, CA [member]
Tourmaline Bio, Inc., New York, NY [member]
Borrowings, adjustment to interest rate basis
Cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities
Acquisitions of businesses
Net cash flows
Acquisitions of businesses
Acquisitions applying the optional concentration test
Other investing cash flows, net
Effect of Pillar Two tax legislation
Tax impact on intercompany transactions
Other receivables
Number of centers that filed ADR proceedings
Impact of acquisitions applying the optional concentration test
Later than five years and not later than six years
Other current assets
Net Cash Flows Used In Acquisitions And Divestments Of Businesses Classified As Investing Activities
Acquisitions and divestments of businesses, net
Property, plant and equipment recognised as of acquisition date through acquisitions applying the optional concentration test
Right of use assets as of acquisition date through acquisitions applying the optional concentration test
Acquired research and development intangible assets recognised as of acquisition date through acquisitions applying the optional concentration test
Deferred tax assets recognised as of acquisition date through acquisitions applying the optional concentration test
Non-current financial and other assets through acquisitions applying the optional concentration test
Other current assets recognised as of acquisition date through acquisitions applying the optional concentration test
Cash and cash equivalents recognised as of acquisition date through acquisitions applying the optional concentration test
Current and non-current lease liabilities through acquisitions applying the optional concentration test
Trade payables and other liabilities through acquisitions applying the optional concentration test
Acquisitions applying the optional concentration test right of use assets
Impact of acquisitions applying the optional concentration test
Acquisitions applying the optional concentration test intangible assets and goodwill
Impact of acquisitions applying the optional concentration test
Increase decrease through acquisitions applying the optional concentration test deffered lax liability asset
Impact of acquisitions applying the optional concentration test
Infrastructure investments [member]
Infrastructure investments
Private equity investments [member]
Private equity investments
Percentage of plan assets investments
Plan assets percentage allocation
Acquisition commitments [abstract]
Acquisition commitments [table]
Avidity Biosciences, Inc.
Avidity Biosciences, Inc. [member]
Acquisition commitments [line items]
Hedge fund investments [member]
Hedge fund investments
Acquisitions applying the optional concentration test property, plant and equipment
Impact of acquisitions applying the optional concentration test
AAA602 and AAA802 [member]
Other finance income
Friedrich Miescher Institute for Biomedical Research [member]
Trade payables and other liabilities through acquisitions applying the optional concentration test
Current and non-current lease liabilities through acquisitions applying the optional concentration test
Portion of consideration paid received consisting of cash and cash equivalents upfront payment for acquisitions applying the optional concentration test
Acquisitions and divestments net through business combinations right of use assets
Impact of acquisitions and divestments of businesses, net
Impact of acquisitions and divestments of businesses, net
Weighted average duration of defined benefit obligation
Weighted average duration of defined benefit obligation years
Estimate of benefit payments expected to be paid from defined benefit plan
Expected future benefit payment
Amount of change in OCI when POS for level 3 change more than 10%
Net loss recorded on equity securities and fund investments at fair value through the consolidated income statement
Current prepayments
Prepaid expenses - third party
Other current receivables
Amount of change in income statement when most significant parameters for level 3 change by 10% positively
Amount of change in income statement when most significant parameters for level 3 change by 10% negatively
Divestments of businesses, net
Total consideration transferred for business combinations
Total purchase consideration for business combinations
In-process research and development assets recognised as of acquisition date through acquisitions applying the optional concentration test
Total purchase consideration for business combinations
Acquisitions and divestments of businesses, net
Description of accounting policy for goodwill and intangible assets other than goodwill [text block]
Disclosure of net sales and total of selected non-current assets, geographic information [table text block]
Net sales and total of selected non-current assets, geographic information
Disclosure of net sales by regions [table text block]
Disclosure of net sales of Top 20 brands [table text block]
Disclosure of other revenue [table text block]
Environmental remediation provisions
Environmental remediation provisions [table text block]
Disclosure of current financial debts and derivative financial instruments [table text block]
Cash flows from changes in working capital and other operating cash flow items included in operating cash flow from continuing operations [table text block]
Net assets recognized as a result of acquistions of businesses
Machinery and equipment
Machinery and equipment [member]
Number of acquisitions of businesses applying the business combination acquisition method
Number of acquisitions applying the optional concentration test method
Disclosure of other interim disclosures [abstract]
Other interim disclosures [text block]
dup_1_Equity
dup_1_Summary of equity attributable to Novartis AG shareholders
Cash flows from changes in working capital and other operating items included in operating cash flow from continuing operations [table text block]
Cash flows from changes in working capital and other operating items included in operating cash flow from continuing operations
Disclosure of net sales, by segements and regions [table text block]
Net sales by region
Disclosure of operating segments, net sales [table text block]
Net sales
Disclosure of operating segments, net sales of Top 20 products [table text block]
Net sales of Top 20 products
Disclosure of operating segments, other revenue [table text block]
Other revenue
Total other comprehensive income
Increase decrease through transfers and other movements equity
Other movements
Increase decrease through transfers and other movements equity, shares
dup_1_Total movements
Net dividend paid
Net dividend paid
Withholding tax on the gross dividend
Withholding tax on the gross dividend
Long-term financial debt with a carrying amount
Cash flows used for acquisitions and divestments of businesses, net
Impairment loss recognised in profit or loss, right-of-use assets
Impairment loss recognised in profit or loss, right of use assets
Impairment loss recognised in profit or loss, right of use assets
Reversal of impairment loss recognised in profit or loss, right-of-use assets
1.600% CHF 650 million bond 2027 of Novartis AG Basel Switzerland, issued at 100.138% [member]
1.650% CHF 435 million bond 2031 of Novartis AG Basel Switzerland, issued at 100.148% [member]
1.750% CHF 645 million bond 2034 of Novartis AG Basel Switzerland, issued at 100.229% [member]
1.850% CHF 280 million bond 2040 of Novartis AG Basel Switzerland, issued at 100.268% [member]
1.850% CHF 190 million bond 2049 of Novartis AG Basel Switzerland, issued at 100.149% [member]
SOFR + 0.65% USD 500 million 2026/2029 Novartis Capital Corporation, New York, United States, issued at 100.000% [member]
4.100% USD 1 250 million 2026/2029 Novartis Capital Corporation, New York, United States, issued at 99.883% [member]
4.400% USD 1 750 million 2026/2031 Novartis Capital Corporation, New York, United States, issued at 99.960% [member]
4.600% USD 2 000 million 2026/2033 Novartis Capital Corporation, New York, United States, issued at 99.574% [member]
4.900% USD 2 250 million 2026/2036 Novartis Capital Corporation, New York, United States, issued at 99.719% [member]
5.600% USD 1 000 million 2026/2046 Novartis Capital Corporation, New York, United States, issued at 99.536% [member]
5.700% USD 2 250 million 2026/2056 Novartis Capital Corporation, New York, United States, issued at 99.120% [member]
Acquisition of assets (right of use assets) through leasing
3.100% EUR 600 million 2026/2032 of Novartis Finance S.A., Luxembourg, Luxembourg issued at 99.525% [member]
3.500% EUR 600 million 2026/2035 of Novartis Finance S.A., Luxembourg, Luxembourg issued at 99.757% [member]
4.000% EUR 500 million 2026/2041 of Novartis Finance S.A., Luxembourg, Luxembourg issued at 99.833% [member]
Excelergy, Inc. [member]
dup_2_AveXis, Inc.
Upfront payment
Additional payments
Marketable securities recognised as of acquisition date
Marketable securities recognised as of acquisition date
Other current assets recognised as of acquisition date
Other current assets recognised as of acquisition date
Excellergy, Inc. [member]
Excellergy, Inc.
Pikavation Therapeutics, Inc. [member]
Pikavation Therapeutics, Inc.
DM1 [member]
Contingent consideration payables [member]
Current contingent consideration receivables [member]
Non-current contingent consideration receivables [member]
Myricx Bio [member]
dup_3_AveXis, Inc.
Bonds issued in the period
Other non-current liabilities as of acquisition date
Current liabilities recognised as of acquisition date
Current liabilities
Other non-current liabilities as of acquisition date
Other current and non-current assets recognised as of acquisition date through acquisitions applying the optional concentration test
Current and non-current liabilities recognised as of acquisition date through acquisitions applying the optional concentration test
Current and non-current liabilities recognised as of acquisition date through acquisitions applying the optional concentration test
Third party sales
Net identifiable assets (acquired) or divested
Total purchase consideration for acquisitions of businesses
Total purchase consideration for acquisitions of businesses
Cash acquired recognized as of acquisition date
Cash acquired recognized as of acquisition date through acquisitions applying the optional concentration test
Cash acquired [member]
Cash acquired
Acquired cash